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Abstract 
Circadian rhythm is a biological rhythm with a period about 24 hours, which 
coordinates the organismal biological processes with environmental day and night cycle. 
This 24-hour rhythm is exhibited in every cell in the organism and is generated by the 
molecular clock circuitry that comprises transcriptional and translational feedback loops. 
While loss of circadian rhythm or alteration of clock gene expression is broadly observed 
in human cancers, the molecular basis underlying these perturbations and their functional 
implications are poorly understood. MYC oncogene is amplified in more than half of the 
human cancers. Its encoded protein, MYC, is a transcription factor that binds to the E-
box sequence (5’-CACGTG-3’), which is the identical binding site of the master 
circadian transcription factor CLOCK::BMAL1.  Thereby we hypothesized that 
deregulated circadian rhythm in cancer cells is a consequence of perturbation of E-box-
containing clock genes by ectopically overexpressed MYC.  
In this thesis, we provide evidence that MYC or N-MYC activation alters 
expression of E-box-containing clock genes including PER1, PER2, REV-ERBα, REV-
ERBβ and CRY1 in cell lines derived from human Burkitts lymphoma, human 
osteosarcoma, mouse hepatocellular carcinoma and human neuroblastoma. MYC 
activation also significantly suppress the expression and oscillation of the circadian 
transcription factor BMAL1. Although public available MYC ChIP-seq data suggest that 
MYC directly binds to the promoter of PER1, PER2, REV-ERBα, REV-ERBβ and CRY1 
in U2OS cells, only silencing of REV-ERBα and REV-ERBβ is able to rescue BMAL1 
suppression by MYC. Strikingly, in two independent patient cohorts, high REV-ERBα 
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and low BMAL1 expression are associated with more aggressive tumor and poorer 
clinical outcome of patients with neuroblastoma. Moreover, overexpressing BMAL1 
suppresses colony formation of neuroblastoma cells. Finally, activation of MYC also 
greatly perturbs glucose metabolism and phospho-AMPK oscillation in U2OS cells.  
To further analyze MYC effects on circadian clock in vivo, we manipulated 
Drosophila Myc (dMyc) level using genetic models and assess their circadian locomotor 
behavior. Here, we have demonstrated that overexpressed dMyc in specific clock cell 
type resulted in reduction of rhythmicity. dMyc activation is able to induce several clock-
controlled genes, including per, tim, cry and cwo. However, no suppression of clk, 
Drosophila homolog of mammalian BMAL1 is observed. Reduction of the clock 
synchronizing peptide PDF in the fly brain observed by immunohistochemistry and 
reduction of valine and leucine in the fly heads measured by GC-MS suggested that 
dMyc-associated arrhythmicity can be resulted from perturbation of PDF level or branch-
chain amino acid metabolism. To explore how endogenous dMyc affect circadian 
behavior of flies, we also examine the circadian behavior in dMyc hypomorph mutant 
flies. Surprisingly, loss of dMyc leads to bimodal distribution of rhythmicity, which can 
be rescued by mutation of dMnt, a known suppressor of dMyc activity. 
Immunohistochemistry revealed Per staining is dramatically diminished in arrhythmic 
dMyc mutant flies but not in rhythmic dMyc mutant flies and can be rescued by dMnt 
mutation, suggesting endogenous dMyc is essential for Per expression. Our results 
demonstrate a novel role of dMyc in maintaining the integrity of Drosophila circadian 
locomotor behavior. Together, our data showed that a novel role of MYC and dMyc in 
modulating the molecular clock in cancer cells and in Drosophila. While MYC induces 
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E-box gene REV-ERBα to suppress BMAL1 and clock-regulated metabolism in cancer 
cells, dMyc is required to maintain E-box gene Per expression to ensure adequate 
circadian behavior. Our findings not only provide therapeutic opportunities between non-
oscillatory cancer cells and circadian-regulated normal cells but also create a new avenue 
for the role of physiological dMyc in Drosophila circadian clock regulation. 
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The MYC proto-oncogene is frequently deregulated in human cancers, activating genetic 
144programs that orchestrate biological processes to promote growth and proliferation 
(Da145ng, 2012). Altered metabolism characterized by heightened nutrients uptake, 
enhanced glycolysis and glutaminolysis and elevated fatty acid and nucleotide synthesis 
is the hallmark of MYC-driven cancer (Dang, 2013; Hsieh et al., 2015). Recent evidence 
strongly suggests that MYC- dependent metabolic reprogramming is critical for 
tumorigenesis, which could be attenuated by targeting specific metabolic pathways using 
small drug-like molecules. In contrast, metabolic pathways in non-proliferating cells are 
largely regulated by circadian clock (Bass, 2012). However, how MYC unleashes 
growth-promoting metabolic processes from circadian constraints is unknown. This thesis 
uses both in vitro and in vivo models to define the role of ectopic MYC and endogenous 
dMyc in circadian clock regulation. 
MYC is an E-Box transcription factor 
MYC was first discovered as a cellular homolog of v-myc, a retroviral gene that was 
found to induce tumorigenesis in birds (Duesberg and Vogt, 1979; Vennstrom et al., 
1982). Its role in human cancer was first recognized through observations of the 
pathognomonic chromosomal translocations, which juxtaposed the MYC gene next to 
constitutively active immunoglobulin enhancers, in human Burkitt’s lymphoma (Dalla-
Favera et al., 1982; Taub et al., 1982). 
The MYC proto-oncogene is aberrantly overexpressed in over half of human cancers 
(Dang, 2012). It is one of the most frequently amplified oncogene in human cancers and a 
member of the larger MYC family, which includes MYCN and MYCL (Brodeur et al., 
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1984; Nau et al., 1985). Dysregulations of MYC, such as amplification, chromosome 
translocation or loss of upstream repressors, have been found in many human cancers 
(Beroukhim et al., 2010; He et al., 1998). 
MYC encodes the MYC transcription factor, which dimerizes with MAX – another helix–
loop–helix leucine zipper protein – to bind DNA and alter gene expression. MYC belongs 
to the extended MYC transcriptional factor network that includes MAX, MXD proteins, 
MGA, MNT, MXL, MXLIP, and the carbohydrate response element binding protein 
(ChREBP) (Carroll et al., 2015). MYC, as a transcriptional factor, activates many genes 
that are involved in cellular processes, including transcription, translation, chromatin 
modification and protein degradation. 
MYC is downstream of a number of growth-promoting signaling pathways, including 
those initiated by growth factor-stimulated receptor tyrosine kinases, T cell receptors and 
WNT signaling (Dang, 2012). In non-transformed cells, cell cycle checkpoints protect 
against aberrant MYC activity. For example, p53-dependent apoptosis is induced upon 
acute MYC overexpression in primary mouse embryo fibroblasts (Eischen et al., 1999). 
MYC also induces expression of ARF, which directly inhibits MYC-mediated 
transcription and tumorigenesis in a p53- independent manner (Qi et al., 2004). In 
transformed cells, however, MYC activation selects for surviving cells that have mutation 
or deletion of p53 or ARF to prevent apoptosis (Eischen et al., 1999). 
The indispensable role of MYC in cancer has been observed in both human cell lines and 
murine models. In human Burkitt’s lymphoma cell line, loss of MYC was found to hinder 
cell proliferation (Yustein et al., 2010). In a mouse model with liver specific, doxycycline 
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(DOX)- suppressed MYC transgene, MYC activation by withdrawal of DOX gives rise to 
aggressive liver tumors that resemble human hepatocellular carcinoma (Shachaf et al., 
2004). Intriguingly, these invasive tumors regress when the tumor-bearing animals are re-
exposed to DOX to inactivate MYC (Shachaf et al., 2004). These findings suggest that 
MYC is not only essential for tumor initiation, but also critical for maintenance of 
established tumors, revealing these tumors’ addiction to MYC signaling. 
It is generally thought that MYC activity is largely through its regulation of transcription. 
The key mechanism allowing MYC to globally enhance transcription is through 
augmenting P-TEFb- dependent phosphorylation of RNA polymerase II to release it from 
the paused state to the elongation state (Rahl et al., 2010). Studies further demonstrate the 
presence of MYC at nearly all the open chromatin regions in the genome, eliciting a 
model that MYC is a universal amplifier and the level of amplification purely depend on 
the patterns of open chromatin within the genes (Chen et al., 2008; Lin et al., 2012; Nie et 
al., 2012). These observations suggest that MYC simply amplifies the existing 
transcriptional program within the cell but it is not clear how MYC modulates the ratio 
between growth-promoting genes versus growth-arresting genes to promote growth and 
proliferation. Follow-up studies have revealed that MYC is able to selectively activate 
expression of certain gene sets while globally enhance transcription (Sabo et al., 2014). 
For instance, overexpressed MYC was found to “invade” enhancers and low affinity core 
promoters that normally bind little MYC at physiological level as it saturates the high 
affinity promoters, suggesting supraphysiological level of MYC preferentially activate 
expression of the genes harboring low affinity promoters or enhancers (Lin et al., 2012; 
Walz et al., 2014; Wolf et al., 2014). Furthermore, high level of MYC recruits MIZ1 
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through protein–protein interaction and enhances MIZ1-dependent repression (Walz et al., 
2014). Together, these findings indicate that while MYC generally augments RNA 
elongation throughout the genome, it does so in cooperation with other transcription 
factors that provide for selective gene expression amplification to coordinate metabolism 
and cell growth (Dang, 2014; Wolf et al., 2014). 
MYC regulation of glucose and glutamine metabolism 
Yeast cells sense glucose and glutamine in the environment and activate expression of 
Ribi genes to initiate ribosome biogenesis (Lippman and Broach, 2009). In Drosophila, 
glucose activates insulin signaling, which acts through PI3K/Akt pathway to activate 
TOR and repress FOXO (Wullschleger et al., 2006). Drosophila Myc (dMyc) is 
identified as a convergent node downstream of TOR and FOXO signaling in response to 
nutrients (Teleman et al., 2008). When glucose is abundant, activated TOR rapidly 
increases dMyc protein to drive ribosome biogenesis. Conversely, when fruit flies are 
under fasting, FOXO is derepressed from Akt and directly inhibits dMyc expression 
(Teleman et al., 2008). In mammals, MYC level was also observed to correlate with 
nutrient level. For example, in rat liver, MYC expression dramatically decreases under 
glucose deprivation (Corcos et al., 1987). Moreover, FOXO3a was found to inhibit MYC 
activity through induction of MYC antagonist MXI1 proteins in colon cancer cells 
(Delpuech et al., 2007). Taken together, the physiological role of MYC as a “nutrient 
sensor” seems to be well conserved during evolution, suggesting that MYC is critical in 
the process of utilizing extracellular glucose and glutamine for macromolecule synthesis. 
The importance of MYC in glucose and glutamine metabolism is further corroborated by 
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heightened glucose and glutamine uptake that observed in neoplastic cells, where 
unleashed MYC is continuously activated. 
Glucose is one of the major nutrients that mammalian cells utilize to synthesize new 
membranes and organelles as well as to generate high energy molecules, such as ATP, 
NADH/NADPH and FADH. Glucose is taken up through glucose transporters (GLUTs) 
and phosphorylated by hexokinase. Glucose-6-phosphate then undergoes a series of 
reversible and irreversible reactions before conversion to two molecules of pyruvates by 
pyruvate kinase with a net production of 2 ATPs and 2 NADHs. Pyruvate can be 
converted to lactate by lactate dehydrogenase (LDH) or to citrate by pyruvate 
dehydrogenase to enter tricarboxylic acid cycle (TCA cycle). 
Many genes involved in glucose metabolism have been documented to be MYC target 
genes. For example, MYC upregulates genes encoding glucose transporters and 
hexokinase to increase glucose import (Osthus et al., 2000). MYC also induces 
expression of glycolytic genes including phosphoglucose isomerase, phosphofructokinase, 
glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and enolase 
(Osthus et al., 2000). Furthermore, use of 13C-labeled glucose has revealed increased 
levels of glycolytic intermediates and lactate in MYC-driven Burkitt’s lymphoma cells, 
suggesting MYC overexpression increases overall glycolytic flux (Le et al., 2010). This 
observation harkens back to findings by Dr. Otto Warburg back in the 1920s indicating 
high rates of glycolysis and lactate production in cancer cells even in the presence of 
oxygen (Warburg et al., 1927). Increased glycolytic flux gives rise to abundant glycolytic 
intermediates that can be used to generate macromolecules such as nucleotides, amino 
acids and fatty acids. To maintain high flux of glycolysis, MYC was observed to 
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upregulate lactate dehydrogenase A (LDHA) to generate NAD+, which is a co-factor 
required for the glycolysis particularly by GAPDH (Le et al., 2010). The role of LDHA in 
MYC-driven cancer cells is underscored by the ability of a specific LDHA inhibitor 
FX11 to cause cell death [54]. MYC has also been shown to regulate alternative splicing 
of the rate-limiting enzyme pyruvate kinase by upregulating heterogeneous nuclear 
ribonucleoproteins (hnRNP) (David et al., 2010). Pyruvate kinase has two distinct 
isoforms: PKM1 and PKM2. While the embryonic pyruvate kinase isoform, PKM2, pro- 
motes aerobic glycolysis, PKM1 favors oxidative phosphorylation. By upregulating 
hnRNPA1 and hnRNPA2, MYC maintains high ratio of PKM2/PKM1 to ensure high 
flux of glycolysis in the presence of oxygen (David et al., 2010). 
Glutamine is another major nutrient for tumor cells, as it fuels the TCA cycle and also 
provides sources of nitrogen. Glutamine is imported into the cells through glutamine 
transporter ASCT2 and is then converted to glutamate by glutaminase (GLS). Several 
enzymes can further metabolize glutamate to α-ketoglutarate (α-KG) to further enter 
TCA cycle including glutamine dehydrogenase (GDH), glutamine pyruvate transaminase 
(GPT) or glutamine oxaloacetate transaminase (GOT). 
Unlike most non-transformed cells that use glucose, MYC-driven cancer cells depend on 
glutamine metabolism (Reitzer et al., 1979). MYC promotes glutamine import by directly 
inducing the expression of glutamine transporter ASCT2 (Wise et al., 2008). In addition, 
MYC increases the conversion of glutamine to glutamate for subsequent oxidation in the 
TCA cycle by upregulating GLS both transcriptionally and post-transcriptionally (Gao et 
al., 2009; Wise et al., 2008). The reliance on glutamine metabolism of MYC-driven 
cancers appears especially true under stress conditions, particularly glucose and oxygen 
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deprivation (Le et al., 2012). Specifically, flux analysis using 13C-labeled glutamine in 
MYC-overexpressing cells has revealed an enrichment of TCA cycle isotopologues under 
glucose-deprivation, suggesting while these cells favor glucose as the carbon sources for 
the TCA cycle, glutamine is an alternative carbon source in the absence of glucose (Le et 
al., 2012). Moreover, MYC overexpression has been shown sufficient to induce 
glutamine addiction. For example, high levels of MYC can convert fibroblasts to become 
addicted to glutamine as evidenced by apoptosis after glutamine withdrawal (Yuneva et 
al., 2007). Intriguingly, TCA cycle intermediates oxaloacetate and pyruvate can rescue 
cell death, suggesting glutamine is the major carbon source for the TCA cycle in these 
MYC- overexpressing cells (Yuneva et al., 2007). Furthermore, knockdown MYC in 
glioma cells can release cells from a glutamine-addicted state (Wise et al., 2008). Given 
the fact that MYC-driven tumor is highly dependent on glutamine, it can be anticipated 
that MYC-driven tumor might be sensitive to inhibitors targeting glutamine metabolism. 
Indeed, decreased cell growth is observed in MYC-overexpressing cancer cells that 
treated with glutaminase inhibitors (Le et al., 2012; Wang et al., 2010). It further appears 
that, when glucose is abundant, the requirement for glutamine may stem from a need for 
glutamate to synthesize glutathione to protect cells against reactive oxygen species (Le et 
al., 2012). Moreover, it was observed that glutamine-derived glutamate contributes to 
MYC-dependent proline synthesis (Liu et al., 2012). 
Cellular homeostasis and growth 
The activation of metabolic pathways is very dynamic and highly dependent on the state 
of cell and the external cues, such as growth signals and nutrients. Mammalian cells 
exhibit two major states in their life: resting state or dividing state. The majority of cells 
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in our body are differentiated and in the resting state, using energy to maintain basal 
metabolism. In contrast, a small population of cells in our body exists in the dividing 
state, including intestinal mucosal cells and hematopoietic cells. These cells have higher 
energy demands for growth and proliferation. 
In resting cells, homeostasis is accomplished by generating sufficient energy from 
extracellular nutrients to sustain protein synthesis, maintain cellular membrane potentials, 
turn over or repair damaged organelles and macromolecules. To maintain a constant level 
of ATP, the major high-energy molecule in the cells, several key factors tightly regulate 
metabolic pathways in response to external nutrient availability. For example, in the 
nutrient-replete state, abundant amino acids activate mTOR complex, which stimulates 
anabolic pathways including protein synthesis, lipid synthesis and ribosomal biogenesis 
(Efeyan et al., 2012). Conversely, under the nutrient-depleted state, low energy induces 
AMP-activated protein kinase (AMPK), which phosphorylates and inhibits the majority 
of anabolic pathways while turning on catabolic, energy-producing pathways including 
glycolysis, oxidative phosphorylation and fatty acid oxidation (Hardie and Alessi, 2013). 
Notably, inactivated mTOR and activated AMPK in response to fasting collectively 
induce autophagy (self-eating), allowing cells to digest their own organelles to produce 
energy and recycle cellular building blocks (Efeyan et al., 2012; Hardie and Alessi, 2013). 
Because food availability and demands for energy-consuming organismal activity are not 
constant, many organisms have evolved systems to anticipate predictable changes and 
thereby optimize metabolic efficiency and enhance evolutionary fitness. One such 
example is circadian rhythm, an autonomous oscillation of biological processes with 
approximately 24-h period, coordinates feeding and sleeping in both unicellular and 
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multicellular organisms. In humans and mice, autonomous cellular metabolic oscillation 
is synchronized with the day–night cycle through a central clock residing in the 
suprachiasmatic nucleus in hypothalamus (Green et al., 2008). The central clock 
synchronizes with light via signals from the retina and in turn sends neuronal and 
hormonal signals to synchronize clocks found in peripheral tissues and cells (Green et al., 
2008). Virtually all cells possess a molecular clock circuity with interlocking feedback 
loops that is comprised of transcriptional activators, such as CLOCK and BMAL1, and 
the transcriptional repressors, PERs, CRYs and REV-ERBs. CLOCK and BMAL1 form a 
complex CLOCK::BMAL1 that binds to the canonical DNA sequence 5’-CACGTG-3’ 
(E-Box) to activate several circadian regulators including PERs, CRYs and REV-ERBs. 
PERs and CRYs form a complex in the cytoplasm and translocate into the nucleus to 
repress CLOCK::BMAL1 transcriptional activity, whereas REV-ERBs directly repress 
BMAL1 expression at retinoic acid receptor-related orphan receptor elements (ROREs). 
These two feedback loops give rise to the observed 24-h oscillation (Green et al., 2008). 
CLOCK::BMAL1 diurnally drives a number of biological pathways, particularly 
metabolic pathways, to coordinate with feeding and sleeping (Bass, 2012). 
Intriguingly, the “E-box” motif used by the CLOCK proteins could also be bound by 
other transcription factors that are involved in metabolism and growth. The carbohydrate-
responsive element-binding protein (ChREBP), sterol regulatory element- binding protein 
(SREBP), microphthalmia-associated transcription	  factor (MITF), transcription factor EB 
(TFEB), transcription factor E3 (TFE3), and oncoprotein MYC (Dang, 2012; Giangrande 
et al., 2003; Sardiello et al., 2009; Yasumoto et al., 1994) are helix–loop–helix proteins 
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that have canonical E-box binding activities, suggesting the possible interplay between 
these transcription factors in regulating metabolism, cell homeostasis and growth. 
We surmise that the E-box motif, which is highly enriched in regulatory sequences of the 
human genome provides a means for transcriptional orchestration of anabolic and 
catabolic metabolism with cell growth and homeostasis (Fernandez et al., 2003). 
Circadian chromatin Immunoprecipitation Sequencing (ChIP-seq) and gene expression 
studies in the mouse liver have found oscillation of genes involved in glycolysis, 
oxidative phosphorylation, lipid synthesis and autophagy, regulated by diurnal BMAL1 
E-box binding (Table 1) (Koike et al., 2012). These BMAL1-regulated metabolic genes 
have also been documented as MYC target genes (Table 1) that exhibit increased 
expression in the MYC-driven murine liver cancer (Fig. 1) (Hu et al., 2011; Lin et al., 
2012). Together these observations suggest that, while BMAL1 diurnally regulates 
metabolism to maintain homeostasis, MYC may substitute for BMALl1 during 
proliferation to activate metabolic genes in a sustained and enhanced manner that 
supports cell growth and division (Dang, 2012) (Fig. 2). Notably, several of these genes 
encode rate-limiting enzymes in the metabolic pathways, such as phosphofructokinase 
(PFK) in glycolysis, HMG-CoA reductase (HMGCR) in cholesterol synthesis pathway 
and NAMPT in NAD+ salvage pathways; thus by controlling the magnitude and temporal 
expression of these genes, MYC can effectively reprogram metabolism. Given these 
observations, we surmise that the ChREBP, SREBP, and MITF/TFE transcription factors 
are also likely to have inter-related activities to control carbohydrate and lipid 
metabolism and autophagy, respectively. These factors along with CLOCK::BMAL1 and  
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the extended MYC transcription factor family form a tapestry of transcription factors that 
orchestrate metabolism and cell growth (Fig. 2). 
Circadian clock and cancer 
Mutations of circadian genes occur in many cancers, but their functional consequences 
are not well understood (Savvidis and Koutsilieris, 2012). Two key circadian genes, 
PER1 and PER2, have been identified as putative tumor suppressors in salivary gland, 
gastro-intestinal system, breast tissue, and the immune compartment (Savvidis and 
Koutsilieris, 2012; Zhao et al., 2014). Loss of PER2 function predisposed genetically 
engineered mice to spontaneous lymphomagenesis, but mouse strain specificity was not 
documented (Fu et al., 2002). Hematologic malignancies such as diffuse large B cell 
lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia show strong 
downregulation of the central circadian regulator BMAL1 (Taniguchi et al., 2009). 
Indeed, recent studies identify BMAL1 as a putative tumor suppressor (Savvidis and 
Koutsilieris, 2012; Yeh et al., 2014). Ovarian cancers have altered circadian gene 
expression and oscillation compared to normal tissue, but the functional significance and 
mechanism for these alterations were not established (Tokunaga et al., 2008). Still other 
studies found circadian gene expression alterations in cancers such as pancreatic, prostate, 
and glioma (Savvidis and Koutsilieris, 2012). Importantly, altered circadian rhythm may 
affect cancer treatment outcomes, as studies in mice and humans have identified 
circadian-dependent toxicity in more than 40 anticancer agents, including antimetabolites, 
mitosis inhibitors, alkylating agents, and cytokines (Levi et al., 2010). Thus, altered  
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circadian gene expression occurs broadly in cancer; however, it is not known whether 
MYC could contribute to disruption of circadian gene expression. 
Myc and circadian rhythm 
Remarkable progress has been made in characterizing genomic regulation of MYC and 
identifying its target genes regulating growth, metabolism, proliferation and apoptosis. 
However, it is unclear how MYC hijacks clock-controlled metabolic pathways in resting 
cells and activates genes that normally oscillating to constitutive expression.  
In Chapter 2 of this thesis, we found that several E-box-containing clock genes were 
induced by MYC in human Burkitts lymphoma, human osteosarcoma and murine 
hepatocellular carcinoma cell lines. Additionally, MYC activation suppresses master 
clock regulator BMAL1 expression and oscillation.  
In Chapter 3, we first demonstrate that MYC directly regulates E-box containing clock 
genes, including PER1, PER2, CRY1, REV-ERBα and REV-ERBβ. We then provide 
evidence that abrogation of REV-ERBα and REV-ERBβ expression using siRNAs 
restores MYC-mediated BMAL1 suppression. 
In Chapter 4, using N-MYC inducible neuroblastoma cell lines, we showed that N-MYC 
similarly represses BMAL1 expression and oscillation through REV-ERBα upregulation. 
Primary neuroblastoma tumor samples from two patient cohorts revealed that elevated 
REV-ERBα and reduced BMAL1 expression predict worse clinical outcome. Finally, 
overexpression of BMAL1 reduced clonogenicity of two neuroblastoma cell lines.  
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In Chapter 5, metabolomic experiments are done to explore the metabolic impacts from 
MYC-mediated BMAL1 suppression. Interesting, MYC activation  abrogates oscillatory 
glucose metabolism and alters glutamine metabolism. In summary, our observations 
describe a previously unrecognized role of MYC in suppression clock and clock-
regulated metabolism to promote cell proliferation in human cancer.  
In Chapter 6, we explored the effect of Drosophila Myc (dMyc) on fly circadian 
locomotor behavior. Interestingly, both gain-of-function and loss-of-function of dMyc 
result in increased arrhythmicity. Overexpression of dMyc in selected clock neurons 
induces clock genes, diminishes circadian synchronizing peptide PDF staining and 
reduces branch chain amino acids in heads of these flies. Loss of dMyc results bimodal 
distribution of rhythmicity and those arrhythmic flies exhibit diminished Per staining in 
central clock neurons. The arrhythmicity and loss of Per can be rescued by additional 
mutation of dMyc repressor dMnt, suggesting dMyc activity is crucial in maintaining 
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It is very clear now that MYC regulates growth and proliferation through activation of 
translation machinery, metabolic pathways and cell cycle progression (Dang, 2012; Hsieh 
et al., 2015; Stine et al., 2015). However, many of these network and pathways are also 
tightly regulated by circadian clock, particularly metabolism (Bass, 2012). Circadian 
clock regulates these pathways to maintain homeostasis, however, when MYC level rises, 
cells are ready to proliferate, it remains unclear how MYC efficiently hijacks the 
homeostatic regulation and turns metabolism into a high speed factory to support cell 
growth and proliferation. As transcription factors, MYC and CLOCK::BMAL1 both 
regulate their target genes through E-box binding. Therefore, we hypothesize that in 
MYC-driven cancer cells, elevated MYC will compete with CLOCK::BMAL1 at the 
promoter of its target genes. As a result, growth and metabolic program that are under 
circadian control by CLOCK::BMAL1 would be activated by MYC constitutively. 
There are a number of inducible MYC model systems that we could utilize to address this 
question. In this chapter, we first examined how ectopic MYC affects clock gene 
expression and oscillation in human P493-6 lymphocytes. In collaboration with Dr. Dean 
Felsher’s laboratory, we engineered and subcloned mouse hepatocellular carcinoma cell 
line to demonstrate that MYC suppresses the expression and oscillation of Bmal1 and the 
suppression could be restored by removing MYC. Finally, in collaboration with Dr. John 
Hogenesch, we found that loss of robust BMAL1 oscillation in osteosarcoma U2OS cells 
upon MYC induction.   
 
Materials and Methods 
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Plasmids 
c-MYC-ER™ wt and Δ106-143, which are responsive to tamoxifen and 4-
hydroxytamoxifen but not to estrogen, were received in the pBabe-puro vector courtesy 
of Dr, Linda Penn, Ontario Cancer Institute, University Health Network, University of 
Toronto, Canada) and were described previously (Littlewood et al., 1995).  c-MYC-ER™ 
wt and Δ106-143 were subcloned into pBabe-Zeo (Morgenstern and Land, 1990) 
(courtesy of Dr. Robert Weinberg, Whitehead Institute for Biomedical Research, 
Cambridge, MA, USA, Addgene plasmid 1766).  Retrovirus was generated in 293T cells 
using the pCMV-VSVG and pUMVC vectors (Stewart et al., 2003) (courtesy of Dr. 
Robert Weinberg, Addgene plasmids 8449 and 8454). 
Cell culture 
P493-6 cells were kindly shared by Dr. Dirk Eick (Munich, Germany). Murine 
hepatocellular carcinoma cell lines (mHCCs) are primary culture tumor cell line, which 
were derived by ring cloning from a liver tumor of the LAP-tTA/tet-OFF cMYC 
conditional transgenic mouse model (Shachaf et al., 2004; Xiang et al., 2015). U2OS 
cells with BMAL1::luciferase vector were kindly shared by Dr. John Hogenesch (Baggs 
et al., 2009).  P493-6 was cultured in Roswell Park Memorial Institute Medium (RPMI 
1640, Mediatech, Manassas, VA, USA). U2OS cells and mHCC cells were cultivated in 
Dulbecco’s modified Eagle’s medium (DMEM, Mediatech, starting glucose 
concentration of 25 mM and starting glutamine concentration of 4 mM).  Media was 
supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA or Life 
Technologies, Grand Island, NY, USA) and 1X Penicillin/Streptomycin (Mediatech) for 
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all cells. mHCC cell media was additionally supplemented with 2 mM L-Glutamine 
(Mediatech), 1 mM Sodium pyruvate (Mediatech) and 1X MEM non-essential amino 
acid (Life Technologies).  To repress c-MYC expression (LOW Myc cells), P493-6 cells 
were treated with 0.1µg/ml Tetracycline (sigma) for 48 hours. To generate 
INTERMEDIATE Myc cells, P493-6 cells were treated with both 0.1µg/ml Tetracycline 
(sigma) and 1 µM beta-estrodiol and let them adapt for about a week. To induce MYC-
ER nuclear translocation, U2OS MYC-ER™ cells were treated with 500 nM 4-
hydroxytamoxifen (Sigma, St. Louis, MO, USA) for 24 hour or treated with same amount 
of ethanol as control.  To repress c-MYC expression, mHCC 3-4 cells were treated with 
20ng/ml tetracycline (Sigma) or treated with media as control. 
U2OS BMAL1::Luc cells were stably transduced with MYC-ER™, MYC-ER™ Δ106-
143, or pBabe-Zeo empty vector retrovirus using the plasmids and methods described 
above.  Infected cells were selected for with 100 µg/ml Zeocin (Life Technologies) for 
two weeks, then continually cultured in Zeocin except during experiments. 
To generate mHCC 3-4 stably expressing luciferase reporter constructs, plasmids (REV-
ERBα::Luc described above or BMAL1::Luc in pGL 4.27 [Promega (Baggs et al., 2009)] 
were linearized by digestion with Not1 (New England Biolabs) and purified by QIAquick 
PCR purification kit (Qaigen).  mHCC 3-4 cells were then transfected with linearized 
plasmids using Lipofectamine 2000 (Life Technologies) and selected with Hygromycin 
(Mediatech) at the following concentrations: 0.8 mg / ml for mHCC 3-4. 
To create stable single-cell mHCC 3-4 Bmal1::Luc clones, cells were trypsinized and 
serially-diluted to 100 cells per 96 well plate. Clones were lysed and mixed with 
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luciferase assay reagent (Promega) and luciferase activity was measured by luminometer. 
Only the clones with 10000 or above relative light units were selected.  Selected clones 
were cultured with 20ng/ml tetracycline in regular media for mHCC cells (as described 
above) for 24 hours. The clones were then screened in Lumicycle™ luminometer (details 
described in Lumicycle section), and those that showed BMAL1::Luciferase oscillation 
were used.  
All cell culture, except that during live-cell luminometer experiments (see Lumicycle 
section below), was conducted in a 5% CO2 humidified atmosphere. 
Real-Time PCR 
All RNAs were extracted by RNeasy Plus Mini Kit (Qiagen) according to 
manufacturer’s instruction and reversed to complementary DNA by using TaqMan 
Reverse Transcription Reagents (Life Technologies).  cDNA was used as template to 
proceed to quantitative real time PCR (RT-PCR) with specific human or mouse primers. 
RT-PCRs were performed using the StepONE Plus system, 7900HT Real-time PCR 
System, or ViiA™ 7 Real-time PCR system (Life Technologies). Relative mRNA 
expression levels were normalized to β2M and analyzed using comparative delta-delta 
CT method. All RT-PCR primers are listed in Table 2. 
Western blot analysis 
Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Fisher 
Scientific) buffer supplemented with protease inhibitor cocktail (BD Biosciences, San 
Jose, CA) and phosphatase inhibitors (Sigma).  Proteins were separated by SDS-PAGE 
using Criterion pre-cast gradient gels (Bio-Rad, Hercules, CA, USA).  Primary antibodies 
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used include: rabbit anti-MYC (Abcam) and mouse anti-α-Tubulin (EMD Millipore, 
Billerica, MA, USA).  Secondary antibodies used include: Alexa-Flour 680 goat anti-
rabbit IgG (Life Technologies, Grand Island, NY). Immunoblots were imaged with the 
Odyssey CLx infrared imaging system (Licor) and uniformly contrasted. 
Circadian mRNA Experiments 
Circadian mRNA experiments for U2OS MYC-ER™, mHCC 3-4 and mHCC EC4 were 
carried out in the media described above as a ‘split timecourse’.  24 hours prior to the 
start of the experiment, half the cells were cultured in 0.1 µM dexamethasone (dex,  
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Sigma), and at the start of the experiment, the other half of the cells were cultured in 
dexamethosone.  At each timepoint, two plates were harvested representing 0 and 24 
hours +dex, 4 and 28, etc, to arrive at a 52 hour timecourse.  mRNA was processed and 
analyzed as described above. 
Lumicycle 
Lumicycle analysis of U2OS BMAL1::Luc cells was described previously (Baggs et al., 
2009).  Briefly, three days prior to analysis, cells were plated in 35 mm dishes at a 
concentration of 250,000 cells / plate.  24 hours later, cells were transfected with siRNA 
as described above.  48 hours post transfection, cells were cultured atmospheric 
conditions, in phenol red-free DMEM (Sigma, St. Louis, MO, USA) containing 5% FBS 
(Hyclone or Gibco), 25 mM D-glucose (Sigma), 35 mg/L sodium bicarbonate (Gibco), 10 
mM HEPES (Gibco), Pen/Strep (Mediatech), 0.1 mM beetle-luciferin (Promega), and 0.1 
µuM dexamethasone (Sigma), and dishes were sealed with high vacuum grease (Dow 
Corning, Midland, MI, USA).  Plates were measured for luminescence every 10 minutes 
for at least 4 days on a Lumicycle™ luminometer (Actimetrics, Wilmette, IL, USA).  The 
experiment for mHCC 3-4 BMAL1::Luc cells was performed in the same way, except 




Clock gene expression and oscillation in P493-6 lymphocytes 
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To address the question whether aberrant c-MYC overexpression would disrupt the 
molecular clock, we first used MYC-inducible, tetracycline (Tet)-repressive cell line 
P493-6 that has been used in previous study from the lab (Yustein et al., 2010). P493-6 
cells were derived from human Burkitts lymphoma and were engineered with a Tet-
repressive ectopic MYC vector and an EBNA2-ER fusion protein. EBNA2-ER fusion 
protein restricts the expression of endogenous MYC only in the presence of estradiol. 
Therefore, ectopic MYC is induced in the absence of tetracycline and endogenous MYC 
can be induced when the cells are exposed to estradiol. P493-6 cells thus have three states: 
HIGH MYC (-Tet), LOW MYC (+Tet) and INTERMEDIATE MYC (+Tet + estradiol) 
(Fig. 3) (Yustein et al., 2010). HIGH MYC cells express significant higher level of MYC 
protein and grow much faster than either INTERMEDIATE MYC or LOW MYC cells 
(Fig. 3). 
We first examine core clock gene expression in HIGH MYC and LOW MYC cells by 
harvesting RNA every 4 hours for 48 hours after synchronizing cells with 50% of fetal 
bovine serum (FBS), which has been shown to synchronize cultured cells up to three 
consecutive days (Balsalobre et al., 1998). As shown in Fig. 4, PER2, REV-ERBα and 
CLOCK is upregulated by MYC among all time points. Selected genes that are 
documented under the control of circadian rhythm, such as Nicotinamide 
phosphoribosyltransferase (NAMPT) and SIRT1 (Fig. 4), are also strongly induced by 
Myc. Interestingly, central clock gene BMAL1 is not detectable (Fig 6A) among all time 
points. 
Despite the change in the expression level of several core clock genes upon MYC 
induction, there is no appreciable oscillation of all the genes we examined even in LOW  
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MYC cells. Lack of circadian oscillation in LOW MYC cells could be explained by two 
reasons. First, LOW MYC cells are usually sicker and it is possible that loss of rhythm is 
a manifestation of sick cells. Second, BMAL1 could be silenced at the genetic or 
epigenetic level in P493 cells. In fact, previous literature has documented that Bmal1 is 
epigenetically silenced in human hematopoietic cancers (Taniguchi et al., 2009). 
Since there is no detectable clock gene oscillation in LOW MYC, we then study mRNA 
expression in INTERMEDIATE MYC cells. The fact that these endogenous MYC-
expressing cells are still able to grow eliminate the concern of these cells being too sick 
(Fig. 3). Previous literature has demonstrated that endogenous MYC exhibits circadian 
rhythm and it is also a target of PER2 in mice (Fu et al., 2002). Therefore, we suspected 
that INTERMEDIATE MYC cells are likely to exhibit circadian rhythm. As shown in Fig 
3, INTERMEDIATE MYC cells express minimal MYC protein level compare to HIGH 
MYC cells. However, in contrast to LOW MYC cells, INTERMEDIATE MYC cells are 
still able to proliferate with a much slower speed compare to HIGH MYC cells (Fig. 3). 
When we examine the clock gene expression in INTERMEDIATE MYC cells for 48 
hours, as expected, E-box containing genes such as PER1, PER2 and REV-ERBα are 
upregulated in HIGH MYC cells compare to INTERMEDIATE MYC cells (Fig. 5). The 
ratio of expression level of these genes between HIGH MYC cells and INTERMEDIATE 
MYC cells, however, is smaller. Notably, the expression of NAMPT is not different in 
HIGH MYC cells versus INTERMEDIATE MYC cells (Fig. 5). This observation 
suggests that NAMPT induction might already be saturated even with minimal MYC 
elevation. BMAL1 remains undetectable in INTERMEDIATE MYC cells. Surprisingly, 
the expression of BMAL1 paralog BMAL2 is dramatically induced in INTERMEDIATE 
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MYC cells (~500 fold) compare to HIGH MYC cells (Fig. 6B). The mechanism of how 
BMAL2 is induced as well as the functional significance of high level of BMAL2 in 
INTERMEDIATE MYC cells still requires further investigation. Unfortunately, we are 
still unable to appreciate circadian oscillation of clock genes in INTERMEDIATE MYC 
cells (Fig. 5), suggesting perhaps there is an irreversible disruption of the molecular clock 
in P493-6 cells regardless of MYC expression level. 
 
Clock gene expression and oscillation in mouse hepatocellular carcinoma cell lines 
Having observed that BMAL1 is not expressed in P493-6 cells even in INTERMEDIATE 
MYC cells, it is hard to assess the effect from MYC on circadian rhythm if a cell line 
does not have rhythm to begin with. We went on and search for other MYC-inducible 
models. Previous literature on circadian rhythm often use mouse liver to assess the 
oscillation of core clock components. Ex vivo liver tissue from Per2-luc mice that was 
genetically knock-in a fusion protein of Per2 and luciferase is able to show endogenous 
Per2 oscillation over several days using luminometer recording (Yoo et al., 2004). 
Recent study also showed a significant portion of metabolic genes that are oscillating and 
bound by clock components in mouse liver (Koike et al., 2012. Most interestingly, 
canonical MYC target NAMPT also exhibits a robust cycling in mouse liver, which will 
be an interesting clock output to evaluate the effect of overexpressed MYC on oscillatory 
metabolism (Koike et al., 2012).  
To study the effect of ectopic MYC on clock gene oscillation in liver, we used a human 
MYC-inducible, tetracycline-repressive mouse hepatocellular carcinoma (HCC) mouse  
	   32	  
  
	   33	  
  
	   34	  
model kindly shared by Dr. Dean Felsher. Human MYC is ectopically expressed in these 
mice and is sufficient to induce aggressive mouse liver tumor which would regress after 
giving the mice doxycycline water (Shachaf et al., 2004) (Fig. 8A). This model provides 
us a great tool to study circadian rhythm because not only we can manipulate MYC level 
very easily, the effect of MYC on growth and potentially metabolism is reversible. In 
order to test our hypothesis in vitro, we use cell lines that derived from the mouse HCC. 
First of all, we assess the growth curve in these cell lines in the presence and absence of 
tetracycline. All six lines that derived from the mouse HCC show dramatic growth 
advantage in the absence of tetracycline when MYC is induced (Fig. 7). Among those, 
we choose 3-4 cells because its morphology resembles human hepatocytes. We also 
further characterize EC4 cells due to its dependency on MYC for proliferation. 
Both 3-4 and EC4 cells expressed high level of human c-MYC in the normal culture 
condition. The expression can be turned off upon treatment of tetracycline as short as 6 
hours (Fig. 8B). Twenty-four hours after tetracycline treatment, c-MYC protein is almost 
undetectable on immunoblot (Fig. 8B). To assess that high level of c-MYC protein is 
functional, we examine mRNA expression of two canonical MYC targets, Ornithine 
Decarboxylase 1(Odc1) and Nampt in the presence and absence of tetracycline. As 
expected, both ODC1 and NAMPT are strongly induced in the absence of tetracycline, 
suggesting ectopic human MYC is functionally intact (Fig. 8B).  
Next, we assessed mRNA expression of several core clock genes, including positive 
regulator BMAL1 and negative regulators in the MYC ON state (-Tet) and MYC OFF 
state (+Tet) of mHCC 3-4 and EC4 cells. Similar to P493 cells, E-box containing genes 
Per1, Per2, Cry1, Rev-erbα and Rev-erbβ are significantly induced in the MYC ON state  
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of mHCC 3-4 (Fig. 9). In contrast, central clock regulator Bmal1 is suppressed by MYC 
(Fig. 9). mHCC EC4 cells exhibit similar expression patterns as mHCC 3-4, however, 
Per2 and Rev-erbβ was not significantly induced by MYC in EC4 cells, and Bmal1 is 
actually induced by MYC (Fig. 10). 
It appears that expression of the majority of clock genes is altered upon MYC 
overexpression, so we hypothesized that the oscillation of these clock genes will also be 
disrupted by overexpressed MYC. To assess of the circadian oscillation of these genes, 
we synchronized both mHCC 3-4 and EC4 cells with dexamethasone at time zero, which 
has been shown to synchronize cells and allow cells to oscillate one more day compare 
with serum shock, then we harvested the cells every four hours and analyzed mRNA 
expression of these clock genes. We found Bmal1 mRNA expression is suppressed in the 
later time points and Per2 is slightly induced at most time points. Oscillation of Per2 is 
minimally perturbed by high MYC. In MYC OFF state, Rev-erbα and Rev-erbβ showed 
strong circadian oscillation with peak at 4, 24 hours and trough at 16, 40 hours after 
dexamethasone treatment. This oscillation is greatly disrupted in MYC ON state (Fig 11).  
In EC4 cells, Bmal1 is upregulated at most time points and Per2 is minimally altered (Fig.  
12), which is consistent with Per2 mRNA expression in unsynchronized cells (Fig 10). 
Per1, Rev-erbα, Nampt and Cry1 are greatly induced by MYC at all time points (Fig. 12). 
Notably, while Rev-erbα oscillation appears to be disrupted in MYC ON state, Rev-erbβ 
and Cry1 oscillation is largely intact (Fig. 12). Our observation suggested that elevated 
MYC indeed alters mRNA expression of several components in the molecular clock 
circuitry and the disruption can be reversed when MYC is removed.   
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Generating BMAL1::Luc single clones from mHCC 3-4 cell line 
Bmal1 oscillation in mHCC cells appears to be altered by MYC overexpression, however, 
the weak oscillation of Bmal1 in MYC OFF cells prevent us from observing stronger 
effect of MYC disruption. The weaker oscillation of Bmal1 in MYC OFF cells is a 
possible consequence from a mixed cell population of non-oscillators and strong- 
oscillators. Therefore, we proceed to subclone the cells and identify strong oscillators 
within the heterogeneous population to increase the signal to noise ratio. 
To screen for strong oscillators, a quick and easy assay to determine which clone is 
cycling is critical. In collaboration with Dr. John Hogenesch, we transfect mHCC cells 
with BMAL1::Luc construct, which has a luciferase reporter downstream of the BMAL 
promoter. By using a real-time luminometer, LumiCycle®, allows us to observe 
continuous oscillation of BMAL1 promoter activity every 10 minutes over several days. 
We started with mHCC 3-4 cells because it exhibits relative stronger circadian oscillation. 
mHCC 3-4 cells were cultured in the presence of tetracycline (MYC OFF) while we 
select for strong oscillatory clones. A number of clones, including C12, C4, C8 and C9 
were selected based on high luciferase signals and appreciable oscillation in the presence 
of tetracycline. Strikingly, when tetracycline was withdrawal from these clones (MYC 
ON), BMAL1 oscillation is blunted (Fig. 13). However, although the BMAL1-luc is lower 
in C12, C4 and C9 in MYC OFF cells, BMAL1-luc level is higher in C8 MYC OFF cells 
(Fig. 13). Based on our observation, MYC suppress Bmal1 expression in polyclonal and 
the majority of monoclonal mHCC 3-4 cells, but why some clones still exhibit high level 
of BMAL1-luc under high MYC requires further investigation. These observations 
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corroborate the fact that elevated MYC is able to blunt the oscillation and levels of Bmal1 
promoter activity, and this disruption can be recovered when MYC is removed. 
Next, we are interested to see the expression of other clock components in these single 
clones. mHCC 3-4 C12 was cultured, synchronized and harvested every 4 hours (Fig. 14). 
Surprisingly, mRNA expression of Bmal1 is not consistent with the oscillation with 
Bmal1 promoter activity observed through BMAL1::Luc. Instead, slight phase shift is 
observed in the oscillation of Bmal1 mRNA. This discrepancy between BMAL1::Luc 
promoter oscillation and endogenous Bmal1 mRNA oscillation is unclear and would need 
further investigation. Per2 mRNA oscillates beautifully in MYC OFF cells and only 
slight phase shift is observed in MYC ON cells.  Per1, Rev-erbα and Nampt are 
upregulated by MYC in a similarly way compare with mHCC 3-4 parental cell lines. 
Notably, this strong oscillatory clone C12, exhibits beautiful oscillation of Nampt mRNA 
in the presence of tetracycline (MYC OFF). This oscillation, however, is disrupted when 
MYC is induced. 
 
U2OS clock gene expression and oscillation 
There are two approaches to study the effect of oncogenic MYC on the molecular clock 
circuitry. One way is to turn off MYC in a cell line rely on high levels of MYC to 
maintain its growth, such as P493-6 and mouse hepatocellular carcinoma cell lines. The 
other way is overexpressing MYC in a cell line that normally grows without ectopic 
MYC. U2OS cells are the cell line we used for the second approach.  
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U2OS cell line is derived from human osteosarcoma cells. It normally expresses low 
level of endogenous MYC (Fig. 15A).  The endogenous MYC appears to oscillate and 
response to dexamethasone treatment (Fig. 15A). The U2OS cell line we use (U2OS 
BMAL1::Luc) was engineered with luciferase reporter downstream of BMAL1 promoter 
(Fig. 15B), kindly shared by Dr. John Hogenesch, allowing us to observe BMAL1 
promoter activity continuously using LumiCycle luminometer. In addition, U2OS 
BMAL1::Luc cells, unlike most cancer cell lines, exhibit robust oscillation of BMAL1 
promoter (Fig. 18), serve as a great model system to study circadian rhythm. 
We transfected U2OS BMAL1::Luc cells with MYC-ER construct which expressing 
MYC-estrogen receptor (MYC-ER) fusion protein to study the effect of MYC (Fig. 15B). 
In the presence of estrogen analog 4-hydroxytamoxifen (4OHT), MYC-ER fusion protein 
will translocate into the nucleus and activate MYC target genes (Fig. 15B). We also 
introduced mutant MYC-ER construct (MYC-ER Δ106-143) into U2OS BMAL1::Luc 
cells to serve as control. The MYC-ER Δ106-143 construct expresses a fusion protein 
that is similar to MYC-ER but lacks MYC transactivation domain. Immunoblot showed 
after 24 hours of 4OHT treatment, there is less MYC-ER protein compare to cells treated 
with ethanol, suggesting that MYC-ER protein indeed translocated into the nucleus where 
it was tagged for degradation (Fig. 15C). Similar to other MYC inducible cell lines, 
canonical MYC targets ODC1 and NAMPT are induced in the cells treated with 4OHT 
(MYC ON) compare to the cells treated with ethanol (MYC OFF) cells. In contrast, 
ODC1 was induced in U2OS MYC-ER Δ106-143 cells with much lesser degree and 
NAMPT is not induced (Fig. 15D).  
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Next we checked the expression profile of multiple core clock genes. As expected, 
compare with MYC OFF cells, a number of E-box containing genes in MYC ON cells are 
significantly upregulated, including PER2, CRY1, REV-ERBα and REV-ERBβ. BMAL1, 
consistent with mHCC 3-4, is dramatically suppressed (Fig. 16). Conversely, in U2OS 
MYC-ER Δ106-143 cells, despite mutant MYC-ER fusion protein translocates to the 
nucleus (Fig. 15C), lacking transactivation domain of MYC fails to induce the majority 
of core clock components (Fig. 17).  
Given the observation that MYC-ER in U2OS cells induces several core clock genes, we 
hypothesized that MYC-ER would blunt BMAL1::Luc oscillation similarly to mHCC 3-4 
C12 (Fig 2-11). As expected, BMAL1::Luc oscillates very nicely in MYC-OFF cells but 
the oscillation was dramatically blunted in MYC-ON cells (Fig. 18A). Interestingly, this 
phenomenon is not observed in U2OS MYC-ER Δ106-143 cells in the presence of 4OHT 
(Fig. 18A). Furthermore, BMAL1::Luc oscillation was not altered in U2OS BMAL1::Luc 
parental cells or empty vector transfected cells in the presence of 4OHT (Fig. 18B). 
The dramatic disruption of BMAL1::Luc in MYC-ON cells suggests that the major clock 
regulator is profoundly affected in the presence of elevated MYC-ER. We are curious to 
see whether endogenous BMAL1 oscillation will be blunted in a similar way as 
BMAL1::Luc. Indeed, endogenous BMAL1 is suppressed and its oscillation was severely 
disrupted in MYC-ON cells (Fig. 19). PER2 and CRY1 showed nice circadian oscillation 
in MYC-OFF cells. However, their mRNA oscillation is greatly disrupted in MYC-ON 
cells. Consistent with what we observe in unsynchronized cells, elevated MYC induces 
PER2, REV-ERBα, CRY1 and NAMPT expression across all time points. In addition, the  
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period of mRNA oscillation of these genes in MYC-ON cells also appears to be shorter 
than MYC-OFF cells.  
 
Discussion 
In this chapter, we have demonstrated that overexpressing of oncogenic MYC can 
suppress and disrupt the oscillation of major clock regulator BMAL1 and induce E-box 
containing clock genes, including PER1, PER2, REV-ERBα, REV-ERBβ and CRY1 in 
several different MYC-inducible cell models. The mechanism in which E-box 
transcription factor MYC replaces CLOCK::BMAL1 to regulate clock genes has been 
implicated from previous research on other E-box binding transcription factor, such as 
Usf1. Usf1 has been shown to activate Per1, Per2, Cry1 and Cry2 in Clock mutant 
(ClockΔ19) mouse liver and rescue the period lengthening of wheel-running in these mice 
(Shimomura et al., 2013). Genome-wide ChIP-Seq analysis revealed an increase in the 
Usf1 binding sites in ClockΔ19 mice compare to wild type mice, suggesting that Usf1 
replace Clock binding sites when ClockΔ19  binding affinity is low (Shimomura et al., 
2013). Consistent with Usf1-induced Per expression, our result showed overexpressed 
MYC, which might have equivalent or higher E-box binding affinity compare to 
CLOCK::BMAL1, could also induce Per expression likely through direct binding. 
Furthermore, MYC overexpression during the development of embryonic stem cells has 
been demonstrated to suppress emergence of mBmal1 and PER2 oscillation (Umemura et 
al., 2014). 
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Suppression of Bmal1 expression and oscillation in mHCC 3-4 and U2OS MYC-ER cells, 
however, is probably not due to direct suppression from MYC since there is no E-box at 
Bmal1 promoter. Interestingly, clock genes that are induced by MYC, including PER1, 
PER2, REV-ERBα, REV-ERBβ and CRY1, are all negative regulators of BMAL1. 
Whether suppression of BMAL1 is due to elevation of these repressors of BMAL1 either 
by inhibiting its activity or its expression, additional studies in Chapter 3 will help to 
elucidate the mechanism. Notably, Bmal1 is elevated by MYC in mHCC EC4 cells, 
suggesting there is heterogeneity in rewiring the circadian circuitry in cancer cells. This 
heterogeneity is well-addressed in recently published article showing that transient 
transfection of c-MYC in human colorectal cancer cell line HCT116 resulted in reduction 
of PER1 expression, which is opposite from what we observed in four cell lines we tested 
here (Repouskou and Prombona, 2016). 
Our finding in P493 cells revealed that although BMAL1 expression is completely not 
detectable regardless of MYC level, BMAL2 is induced dramatically in 
INTERMEDIATE MYC cells. BMAL2 has been shown to be a functionally redundant 
paralog of BMAL1, supported by the observation that constitutively expressing BMAL2 
is able to rescue the arrhythmicity and metabolic phenotypes of Bmal1-knockout mice 
(Shi et al., 2010). However, even with high level of BMAL2 expression in 
INTERMEDIATE Myc cells, the oscillation of PER1 or PER2 is still hard to appreciate, 
suggesting BMAL2 might not be functionally redundant in P493 cells, at least in 
circadian clock control. Notably, BMAL2 is amplified in about 10-15% ovarian cancer, 
testicular cancer and neuroendocrine prostate cancers (Cerami et al., 2012; Gao et al., 
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2013), which implicated that the huge surge of BMAL2 expression in INTERMEDIATE 
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Chapter 3  
Investigation of REV-ERBα as a direct MYC target gene for 
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Circadian rhythm consists of positive regulators and negative regulators. Positive 
regulator CLOCK and BMAL1, form heterodimer and bind to E-box to drive the 
expression of its target genes or negative regulators. These negative regulators, including 
PERs, CRYs and REV-ERBs, form two major feedback loops to suppress CLOCK and 
BMAL1. The first feedback loop is formed by the protein complex of PER and CRY, 
which inhibits the activity of CLOCK::BMAL1 heterodimer. The second loop is through 
the repression of BMAL1 transcription by REV-ERBs. The time delay from the 
transcription and translation of the positive regulators and negative regulators is the 
molecular basis of circadian oscillation. 
In Chapter 2, we have used several different MYC-inducible models to demonstrate that 
overexpressed oncogenic MYC is sufficient to suppress BMAL1 expression. By examine 
mRNA expression of various core clock components; we have discovered that MYC also 
induces several clock-controlled genes, particularly PER2, CRY1 and REV-ERBs across 
different cell lines. Interestingly, these “clock-controlled genes” are all repressors of 
CLOCK::BMAL. The observation of induction of negative regulators and suppression of 
Bmal1 suggests a potential mechanism that happening in cancer cells: MYC suppress the 
molecular clock by upregulating clock repressors. Several clock genes have been 
associated with cancer. For instance, previous study showed that Per2 as a tumor 
suppressor and is able to regulate endogenous MYC in several cancers. REV-ERBα has 
been documented to be amplified in ERBB2-positive human breast cancer (Kourtidis et 
al., 2010). CRY1 has been reported to be epigenetic silencing in chronic lymphocytic 
leukemia (Hanoun et al., 2012). However, there is no evidence so far that suggest which 
clock repressor is downstream of oncogenic MYC.  
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In this chapter, we provide evidence from public available dataset that several clock 
repressors are indeed direct MYC targets and MYC binding sites are well conserved. 
Among these clock repressors, we are able to demonstrate that only REV-ERBα and 
REV-ERBβ are responsible for suppressing BMAL1 expression and oscillation upon 
MYC overexpression. Finally, we showed that knockdown of both REV-ERBα and REV-
ERBβ is able to rescue BMAL::Luc level and oscillation.  
Materials and Methods 
Plasmids 
c-MYC-ER™ wt and Δ106-143, which are responsive to tamoxifen and 4-
hydroxytamoxifen but not to estrogen, were received in the pBabe-puro vector courtesy 
of Dr, Linda Penn, Ontario Cancer Institute, University Health Network, University of 
Toronto, Canada) and were described previously (Littlewood et al., 1995).  c-MYC-ER™ 
wt and Δ106-143 were subcloned into pBabe-Zeo (Morgenstern and Land, 1990) 
(courtesy of Dr. Robert Weinberg, Whitehead Institute for Biomedical Research, 
Cambridge, MA, USA, Addgene plasmid 1766).  Retrovirus was generated in 293T cells 
using the pCMV-VSVG and pUMVC vectors (Stewart et al., 2003) (courtesy of Dr. 
Robert Weinberg, Addgene plasmids 8449 and 8454). 
The promoter region of human REV-ERNα (NR1D1) corresponding to bases -1156 to 
+31, where 0 is the ATG start site, or a region exactly 2000 bases upstream of this, were 
cloned from U2OS BMAL1::Luc genomic DNA harvested by DNEasy Blood and Tissue 
Kit (Qiagen, Gaithersburg, MD, USA) using the Phusion ™ High-Fidelity DNA 
Polymerase (New England Biolabs, Ipswitch, MA), and inserted into the pGL4.15 
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promoterless luciferase construct (Promega, Madison, WI, USA).  The inserts in the 
resulting vector were sequenced by the University of Pennsylvania DNA Sequencing 
Facility and confirmed to not have mutations. 
Cell culture 
Murine hepatocellular carcinoma cell lines (mHCCs) are primary culture tumor cell line, 
which were derived by ring cloning from a liver tumor of the LAP-tTA/tet-OFF cMYC 
conditional transgenic mouse model (Shachaf et al., 2004; Xiang et al., 2015). U2OS 
cells with BMAL1::luciferase vector were kindly shared by Dr. John Hogenesch (Baggs 
et al., 2009). U2OS cells and mHCC cells were cultivated in Dulbecco’s modified 
Eagle’s medium (DMEM, Mediatech, starting glucose concentration of 25 mM and 
starting glutamine concentration of 4 mM).  Media was supplemented with 10% fetal 
bovine serum (FBS, HyClone, Logan, UT, USA or Life Technologies, Grand Island, NY, 
USA) and 1X Penicillin/Streptomycin (Mediatech) for all cells. mHCC cell media was 
additionally supplemented with 2 mM L-Glutamine (Mediatech), 1 mM Sodium pyruvate 
(Mediatech) and 1X MEM non-essential amino acid (Life Technologies. To induce Myc-
ER nuclear translocation, U2OS MYC-ER™ cells were treated with 500 nM 4-
hydroxytamoxifen (Sigma, St. Louis, MO, USA) for 24 hour or treated with same amount 
of ethanol as control.  To repress c-MYC expression, mHCC 3-4 cells were treated with 
20ng/ml tetracycline (Sigma) or treated with media as control. 
U2OS BMAL1::Luc cells were stably transduced with MYC-ER™, MYC-ER™ Δ106-
143, or pBabe-Zeo empty vector retrovirus using the plasmids and methods described 
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above.  Infected cells were selected for with 100 µg/ml Zeocin (Life Technologies) for 
two weeks, then continually cultured in Zeocin except during experiments. 
To generate mHCC 3-4 stably expressing luciferase reporter constructs, plasmids (REV-
ERBα::Luc described above or BMAL1::Luc in pGL 4.27 [Promega (Baggs et al., 2009)] 
were linearized by digestion with Not1 (New England Biolabs) and purified by QIAquick 
PCR purification kit (Qaigen). mHCC 3-4 cells were then transfected with linearized 
plasmids using Lipofectamine 2000 (Life Technologies) and selected with Hygromycin 
(Mediatech) at the following concentrations: 0.8 mg / ml for mHCC 3-4. 
To create stable single-cell mHCC 3-4 Bmal1::Luc clones, cells were trypsinized and 
serially-diluted to 100 cells per 96 well plate. Clones were lysed and mixed with 
luciferase assay reagent (Promega) and luciferase activity was measured by luminometer. 
Only the clones with 10000 or above relative light units were selected.  Selected clones 
were cultured with 20ng/ml tetracycline in regular media for mHCC cells (as described 
above) for 24 hours. The clones were then screened in Lumicycle™ luminometer (details 
described in Lumicycle section), and those that showed BMAL1::Luciferase oscillation 
were used.  
All cell culture, except that during live-cell luminometer experiments (see Lumicycle 
section below), was conducted in a 5% CO2 humidified atmosphere. 
siRNA 
Human or mouse SMARTpool® siRNAs were purchased from Dharmacon (GE 
Healthcare, Lafayette, CO, USA).  Cells were transfected with siRNAs using 
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Lipofectamine 2000 or RNAiMAX (Life Technologies). Non-targeting siRNAs with 
same molar amount were used as negative control. 
ChIP 
Chromatin immunoprecipitation was done by using Imprint® Ultra Chromatin 
Immunoprecipitation Kit, according to manufacturer’s instructions (Sigma).  Briefly, 
cells were washed in PBS, crosslinked in 1% Formaldehyde (Sigma), lysed, sonicated 
and then immunoprecipitated with rabbit anti-MYC antibody (Abcam, Cambridge, MA, 
USA). Myc-bound DNA fragments were reverse crosslinked, eluted and then amplified 
by quantitative RT-PCR. Primer pairs for ChIP assay were: REV-ERBα, 5’-
GCTTTGCCAGGCAGAAAGGGTAAA-3’ and 5’-
GCAACGACAAGACTGTCGGGATTT-3’; REV-ERBα minus 2K, 5’- 
TGGCTTTCATGTTTCCCAGGCA-3’ and 5’- TCCCAGTGCTTCTAGAGAGGGTTT-
3’; NPM1, 5‘-GCTACATCCGGGACTCACC-3’ and 5’- 
GCTGCCATCACAGTACATGC-3’. 
Real-Time PCR 
All RNAs were extracted by RNeasy Plus Mini Kit (Qiagen) according to manufacturer’s 
instruction and reversed to complementary DNA by using TaqMan Reverse Transcription 
Reagents (Life Technologies).  cDNA was used as template to proceed to quantitative 
real time PCR (RT-PCR) with specific human or mouse primers. RT-PCRs were 
performed using the StepONE Plus system, 7900HT Real-time PCR System, or ViiA™ 7 
Real-time PCR system (Life Technologies). 
Luciferase 
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Cells were washed with PBS, lysed with 1X Passive lysis buffer (Promega) and dislodged 
by cell scraper. Cell lysates were then collected, mixed with luciferase assay reagent 
(Promega) and luciferase activity was measured by luminometer. 
Lumicycle 
Lumicycle analysis of U2OS BMAL1::Luc cells was described previously (Baggs et al., 
2009).  Briefly, three days prior to analysis, cells were plated in 35 mm dishes at a 
concentration of 250,000 cells / plate.  24 hours later, cells were transfected with siRNA 
as described above.  48 hours post transfection, cells were cultured atmospheric 
conditions, in phenol red-free DMEM (Sigma, St. Louis, MO, USA) containing 5% FBS 
(Hyclone or Gibco), 25 mM D-glucose (Sigma), 35 mg/L sodium bicarbonate (Gibco), 10 
mM HEPES (Gibco), Pen/Strep (Mediatech), 0.1 mM beetle-luciferin (Promega), and 0.1 
µuM dexamethasone (Sigma), and dishes were sealed with high vacuum grease (Dow 
Corning, Midland, MI, USA).  Plates were measured for luminescence every 10 minutes 
for at least 4 days on a Lumicycle™ luminometer (Actimetrics, Wilmette, IL, USA).  The 
experiment for mHCC 3-4 BMAL1::Luc cells was performed in the same way, except 




Elevated MYC directly upregulates negative regulators of the molecular clock  
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Given the observation that elevated MYC suppresses BMAL1 in both U2OS cells and 
mHCC 3-4 cells (Fig. 9, 16) and induces several negative regulators, including PER2, 
CRY1, REV-ERBα in all cells we tested (Fig 4, 9, 16), we hypothesize that the induction 
of negative regulators by MYC contributes to clock suppression in cancer cells (Fig. 20).  
To delineate whether these clock repressors behave like direct MYC targets, we first 
examine the public available MYC ChIP-seq data in several cancer cell lines from 
ENCODE project using UCSC genome browser (Fig. 21) (Kent et al., 2002; Walz et al., 
2014). PER2, CRY1, REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) promoter has strong 
MYC binding in U2OS cells with MYC overexpression (Fig. 21) and human chronic 
myelogenous leukemia cell line K562 (Fig. 22, 23) However, there is no MYC binding at 
BMAL1 (ARNTL) promoter in these two cell lines. In addition, phylogenetic analysis of 
MYC binding site at PER2 (Fig. 22), CRY1 (Fig. 22) and REV-ERBα (NR1D1) (Fig. 23) 
showed that MYC-bound E-Box is well conserved down to Wallaby (Siepel et al., 2005). 
All these data indicate that PER2, CRY1, REV-ERBα and REV-ERBβ are direct MYC 
targets.  
 
REV-ERBα and REV-ERBβ are critical BMAL1 repressor downstream of MYC 
overexpression 
We then sought to identify the key repressor that is responsible for BMAL1 suppression 
downstream of MYC. While 90% of PER2 and CRY1 expression was knockdown by use 
of small interfering RNA (siRNA), BMAL1 transcript level is not rescued (Fig. 24A and 
B).  Similarly, knockdown of either PER2 or CRY1 fail to rescue the dampened  
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BMAL1::Luc oscillation in MYC-ON cells (Fig. 24C).  In contrast, mRNA levels of 
BMAL1 were rescued partially by either REV-ERBα or REV-ERBβ silencing and were 
completely rescued by siRNAs targeting both REV-ERBα and REV-ERBβ (Fig. 25). 
Strikingly, while in synchronized U2OS MYC-ER cells, the blunted oscillation of 
BMAL1::Luc in MYC-ON cells can be partially rescued by silencing REV-ERBα or 
REV-ERBβ, knockdown REV-ERBα and REV-ERBβ simultaneously results in a nearly 
complete rescue of BMAL1::Luc oscillation (Fig. 26). These data suggest that the 
elevation of REV-ERBα and REV-ERBβ, but not PER2 and CRY1, are the critical 
repressors lead to BMAL1 suppression in MYC overexpressing cells. 
To determine whether REV-ERBα is directly regulated by MYC in the cell model we 
used, we performed Chromatin immunoprecipitation (ChIP) experiment using anti-MYC 
antibody in U2OS MYC-ER cells. Indeed, MYC directly binds to REV-ERBα promoter 
but not at the site 2Kb upstream of REV-ERBα promoter (Fig. 27). In mHCC 3-4 cells, 
Myc-mediated BMAL1 suppression was similarly restored with siRNA targeting against 
Rev-erbα (Fig. 28A). In addition, silencing Rev-erbα also rescue BMAL1::Luc level in 
mHCC 3-4 c12 cells (Fig. 29). To further assess whether MYC directly activate Rev-erbα 
promoter activity, we transduced a luciferase reporter downstream of human REV-ERBα 
promoter into mHCC 3-4 cells (REVα::Luc). As expected, luciferase level is higher in 
mHCC 3-4 REVα::Luc cells when MYC is induced (Fig. 28B). Together, our results have 
demonstrated that REV-ERBα is a direct MYC target in both U2OS MYC-ER cells and 
mHCC 3-4 cells. 
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Discussion 
In this Chapter, we provide evidence that MYC directly upregulates several negative 
regulators of BMAL1, including PER2, CRY1 and REV-ERBs from public available 
ChIP-Seq data in a number of different cancer cell lines. While PERs and CRYs form 
heterodimer and translocate to the nucleus to inhibit CLOCK::BMAL1 activity, REV-
ERBs repress BMAL1 transcription directly (Preitner et al., 2002; Relogio et al., 2011). 
When we knockdown these BMAL1 repressors individually, we found only knockdown 
of REV-ERBα or REV-ERBβ but not PER2 or CRY1 is able to rescue BMAL1 
oscillation and expression in U2OS MycER cells, suggesting REV-ERBs are the major 
downstream factors that act on BMAL1 suppression. REV-ERBα’s strong effect on clock 
suppression has been documented in earlier study where they achieve liver-specific 
Bmal1 knockdown in mouse by constitutively expressed Rev-erbα in mouse liver 
(Kornmann et al., 2007).  In fact, our earlier data showed overexpression of mutant 
MYCΔ106, which lacks transactivation domain of MYC, resulted in elevation of BMAL1 
promoter activity (Fig. 18). This dominant negative effect due to overexpression of 
mutant MYCΔ106 reveal that MYC effect on BMAL oscillation is from transcriptional 
repressors. Furthermore, silencing both REV-ERBα and REV-ERBβ achieve nearly full 
rescue of both expression level and oscillation of BMAL1, indicating both proteins are 
responsible for BMAL1 suppression. Our data documented a novel mechanism in which 
MYC induces a nature clock repressor as a way to constitutively shut down clock and 
perhaps clock-controlled biological processes (Fig. 30).  
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Although knockdown of REV-ERBα is able to partially rescue BMAL1 suppression, 
knockdown both REV-ERBα and REV-ERBβ are required to fully restore BMAL1 
expression and oscillation. Indeed, REV-ERBβ has been shown to collaborate with REV-
ERBα to regulate both clock and metabolism in mouse embryonic fibroblasts as well as 
mouse liver (Bugge et al., 2012). In addition, circadian wheel-running behavior is only 
completely disrupted in Rev-erbα, Rev-erbβ double knockout mice but not in mice that 
loss either Rev-erbα or Rev-erbβ alone (Cho et al., 2012). Overall, our data and 
observations from others suggest that REV-ERBα and REV-ERBβ are not just 
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To test the translational connection of c-MYC disruption of circadian clock in cancer 
cells, we further investigate whether N-MYC also suppresses the molecular clock by 
upregulating REV-ERBα. N-MYC belongs to the same family as c-MYC and shares 
similar sequence and structural components as c-MYC and L-MYC, another oncogene 
that has been linked to lung adenocarcinoma (Fig. 31) (Brodeur et al., 1984; Nau et al., 
1985). N-MYC is an oncogene that drives extremely aggressive childhood cancer 
neuroblastoma (Brodeur et al., 1984; Kohl et al., 1984).  Thus, understanding the role of 
N-Myc in circadian clock can potentially provide clues for better risk assessment and 
developing new therapeutic approach to the patients with neuroblastoma. 
N-MYC has been studied in numerous literature that it drives overlapping target genes as 
c-MYC (Boon et al., 2001; Malynn et al., 2000). Many neuroblastoma cell lines are 
addictive to N-MYC expression, and suppression of N-MYC leads to arrested tumor 
growth (Jiang et al., 2011). Amplification of N-MYC in neuroblastoma has been shown 
in a number of different clinical trials that predict poorer prognosis of neuroblastoma 
patients (Brodeur et al., 1984; Kushner et al., 2014; Slavc et al., 1990). However, how 
overexpressed N-MYC in neuroblastoma affects the molecular clock remains poorly 
understood.  
In this chapter, we first look at the relevance of c-MYC and REV-ERBα in the context of 
human leukemia. We then did detailed studies to determine whether REV-ERBα acts as a 
target gene downstream of N-MYC and we found that REV-ERBα is directly regulated by 
overexpressed N-Myc in two neuroblastoma cell lines. In collaboration with Dr. John 
Maris, we further analyze the expression of REV-ERBα and BMAL1 in human 
neuroblastoma tumor samples. Elevated REV-ERBα and reduced BMAL1 were associated 
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with more aggressive tumor. Strikingly, elevated REV-ERBα and reduced BMAL1 also 
correlate with poorer prognosis of neuroblastoma patients from two independent patient 
cohorts. Lastly, we observed decrease in colony formation in in two patient-derived 
neuroblastoma cell lines upon BMAL1 overexpression, suggesting that BMAL1 is a 
tumor suppressor in neuroblastoma. 
 
Materials and Methods 
Plasmids 
The promoter region of human REV-ERNα (NR1D1) corresponding to bases -
1156 to +31, where 0 is the ATG start site, or a region exactly 2000 bases upstream of 
this, were cloned from U2OS BMAL1::Luc genomic DNA harvested by DNEasy Blood 
and Tissue Kit (Qiagen, Gaithersburg, MD, USA) using the Phusion ™ High-Fidelity 
DNA Polymerase (New England Biolabs, Ipswitch, MA), and inserted into the pGL4.15 
promoterless luciferase construct (Promega, Madison, WI, USA).  The inserts in the 
resulting vector were sequenced by the University of Pennsylvania DNA Sequencing 
Facility and confirmed to not have mutations. 
pCMV6-ARNTL (RC207870) and its empty vector pCMV-entry vector 
(PS100001) were purchased from Origene (Rockville, MD, USA). 
Cell Culture 
Shep N-MYC-ER (Ushmorov et al., 2008), SKNAS N-MYC-ER (Valentijn et al., 2005), 
Shep, NLF, and Kelly were cultivated in Dulbecco’s modified Eagle’s medium (DMEM, 
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Mediatech, Manassas, VA, USA, starting glucose concentration of 25 mM and starting 
glutamine concentration of 4 mM).  Media was supplemented with 10% fetal bovine 
serum (FBS, HyClone, Logan, UT, USA or Life Technologies, Grand Island, NY, USA) 
and 1X Penicillin/Streptomycin (Mediatech) for all cells. Some Shep N-MYC-ER, and 
SKNAS N-MYC-ER cells were treated with 500 nM 4-hydroxytamoxifen (Sigma, St. 
Louis, MO, USA) or ethanol control. 
Primary human T-cells were cultured in RPMI 1640 medium (Mediatech) supplemented 
with 10% FBS (Gemini Bioproducts, West Sacramento, CA), 100 µ/mL 
Penicillin/Streptomycin (Life Technologies), 2 mM L-Glutamine (Life Technologies), 
and 55 µM -mercaptoethanol (Life Technologies).  Cells were activated for 48 hours 
on plates coated with 10µg / ml anti-CD3 and 2.5 µg / ml anti-CD28 (both from 
Ebioscience, San Diego, CA, USA). 
Human T-ALL lines were cultured in the following medium: RPMI 1640 medium 
(Mediatech) supplemented with 100 µ/mL Penicillin/Streptomycin (Life Technologies), 2 
mM L-Glutamine (Life Technologies), and 55 µM -mercaptoethanol (Life 
Technologies).  The following amounts of FBS were used: TALL-1: 15% FBS; ALL-SIL: 
20% FBS; DND-41: 10% FBS; Molt-4: 10% FBS; Jurkat: 10% FBS; HPB-ALL: 20% 
FBS. 
To generate Shep N-MYC-ER cells stably expressing luciferase reporter constructs, 
plasmids (REV-ERBα::Luc described above in pGL 4.27 [Promega (Baggs et al., 2009)] 
were linearized by digestion with Not1 (New England Biolabs) and purified by QIAquick 
PCR purification kit (Qiagen).  Shep N-MYC-ER cells were then transfected with 
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linearized plasmids using Lipofectamine 2000 (Life Technologies) and selected with 
Hygromycin (Mediatech) at the following concentrations: 0.4 mg / ml for Shep N-MYC-
ER. 
All cell culture, except that during live-cell luminometer experiments (see Lumicycle 
section below), was conducted in a 5% CO2 humidified atmosphere. 
ChIP 
Chromatin immunoprecipitation was done by using Imprint® Ultra Chromatin 
Immunoprecipitation Kit, according to manufacturer’s instructions (Sigma).  Briefly, 
cells were washed in PBS, crosslinked in 1% Formaldehyde (Sigma), lysed, sonicated 
and then immunoprecipitated with rabbit anti-MYC antibody (Abcam, Cambridge, MA, 
USA). Myc-bound DNA fragments were reverse crosslinked, eluted and then amplified 
by quantitative RT-PCR. Primer pairs for ChIP assay were: REV-ERBα, 5’-
GCTTTGCCAGGCAGAAAGGGTAAA-3’ and 5’-
GCAACGACAAGACTGTCGGGATTT-3’; REV-ERBα minus 2K, 5’- 
TGGCTTTCATGTTTCCCAGGCA-3’ and 5’- TCCCAGTGCTTCTAGAGAGGGTTT-
3’; NPM1, 5‘-GCTACATCCGGGACTCACC-3’ and 5’- 
GCTGCCATCACAGTACATGC-3’.  
Luciferase 
Cells were washed with PBS, lysed with 1X Passive lysis buffer (Promega) and dislodged 
by cell scraper. Cell lysates were then collected, mixed with luciferase assay reagent 
(Promega) and luciferase activity was measured by luminometer. 
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Real-Time PCR 
All RNAs were extracted by RNeasy Plus Mini Kit (Qiagen) according to manufacturer’s 
instruction and reversed to complementary DNA by using TaqMan Reverse Transcription 
Reagents (Life Technologies).  cDNA was used as template to proceed to quantitative 
real time PCR (RT-PCR) with specific human or mouse primers. RT-PCRs were 
performed using the StepONE Plus system, 7900HT Real-time PCR System, or ViiA™ 7 
Real-time PCR system (Life Technologies). Relative mRNA expression levels were 
normalized to β2M and analyzed using comparative delta-delta CT method. All RT-PCR 
primers are listed below: 
Circadian mRNA Experiments 
 Circadian mRNA experiments for Shep N-MYC-ER, SKNAS N-MYC-ER, Shep, 
NLF, and Kelly were carried out in the media described above as a ‘split timecourse’.  24 
hours prior to the start of the experiment, half the cells were cultured in 0.1 µM 
dexamethasone (dex, Sigma), and at the start of the experiment, the other half of the cells 
were cultured in dexamethosone.  At each timepoint, two plates were harvested 
representing 0 and 24 hours +dex, 4 and 28, etc, to arrive at a 52 hour timecourse.  
mRNA was processed and analyzed as described above. 
Colony suppression assay 
 Kelly and NLF cells were seeded in 6-well plate and transfected with either 
pCMV6-ARNTL vector or pCMV6-entry empty vector (Origene) with Lipofectamine 
LTX with Plus (Life technology) in triplicates with concentrations of 0.2 or 0.8 µg/ml, as 
noted in figure legend. After one day of transfection, both Kelly and NLF cells were 
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cultured in media containing 1mg/ml G418 (Mediatech) for 7-10 days. G418-containing 
media was changed every 2 days. Colonies were stained with crystal violet solution for 
20 min at room temperature and washed with water to remove extra crystal violet 
solution.  Plates were scanned and quantified with ImageJ, and representative images 
were uniformly contrasted. 
Primary Neuroblastoma Data 
 For survival data, previously published data (Wang et al., 2006) for ninety-two 
human tumors was assessed for overall survival based on MYCN and NR1D1 expression. 
Survival analyses were performed using the methods of Kaplan and Meier.  Patients were 
divided into groups based on tertiles of mRNA expression. For overall-survival (OS), 
time was defined as the time from diagnosis until the time of death from disease or until 
the time of last contact if death did not occur.  Patients who were alive were censored at 
the time last known alive.  Log-rank p-values < 0.05 were considered significant.  For 
mRNA expression analyses of primary human neuroblastomas, we analyzed Affymetrix 
Exon ST array data of 240 tumors obtained at diagnosis (Pugh et al., 2013) as part of the 
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) 
project of the National Cancer Institute Office of Cancer Genomics.  Data were 
normalized as described previously.  A Student’s t-test was applied to assess expression 
differences across risk groups as defined by the Children’s Oncology Group (COG), 
accounting for MYCN amplification status.  P < 0.05 was considered significant.  
 
Results 
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REV-ERBα expression is upregulated in human T-cell acute lymphoblastic 
leukemia cell lines 
Given our observation that MYC overexpression renders elevation of REV-ERBα 
transcripts, we further analyze expression of REV-ERBα in T-lineage acute lymphoblastic 
leukemia where c-MYC is often overexpressed. 
T-lineage acute lymphoblastic leukemia (T-ALL) is a childhood blood cancer where 
more than half of them exhibit deregulation of PI3K/AKT pathway ultimately leads to 
elevated c-MYC RNA (Goldman and McGuire, 1992; La Starza et al., 2014).  We 
compare mRNA expression of c-MYC and REV-ERBα in activated human primary T cells 
versus six human T-ALL cell lines (courtesy Dr. Jeffrey Rathmell, Vanderbilt University, 
TN) and found c-MYC is highly upregulated in all T-ALL cell lines compare to human 
activated T cells (Fig. 32A). Interestingly, elevation of REV-ERBα transcripts is observed 
in all T-ALL cell lines which nicely correlate with the level of MYC overexpression (Fig. 
32B). This observation has revealed that perhaps REV-ERBα is a downstream target of 
MYC in human T-ALL cell lines. 
 
REV-ERBα is a direct N-MYC target 
Our previous results have demonstrated that REV-ERBα is directly upregulated by MYC 
in U2OS cells and mHCC 3-4 cells, we further ask a question whether REV-ERBα is also 
a direct target of N-MYC. To address this question, we used two human neuroblastoma 
cell lines: Shep N-MYC-ER and SKNAS N-MYC-ER (Ushmorov et al., 2008; Valentijn 
et al., 2005). Both cell lines do not have MYCN amplification, however, they harbor 
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ectopic N-MYC-ER construct which overexpresses N-MYC in the presence of estrogen 
analog 4-hydroxytamoxifen (4OHT).  Two canonical c-MYC targets ODC1 and NAMPT 
are induced in both Shep N-MYC-ER and SKNAS N-MYC-ER with activation of ectopic 
N-MYC, further demonstrated that N-MYC shares c-MYC target genes (Fig. 34). We 
further assess whether REV-ERBα is similarly upregulated by N-MYC. Indeed, when N-
MYC is induced in Shep N-MYC-ER cells, REV-ERBα mRNA is elevated (Fig. 33A). 
Chromatin immunoprecipitation revealed that N-MYC binds to REV-ERBα promoter but 
not 2 KB upstream of the promoter (Fig. 33B). In addition, elevated N-MYC is able to 
activate REV-ERBα promoter as demonstrated by increased luciferase activity in Shep N-
MYC-ER REVα::Luc cells in the presence of 4OHT (Fig. 33C). In two N-MYC 
amplified human neuroblastoma cell lines (NLF and Kelly), REV-ERBα mRNA is also 
significantly higher compare to parental Shep cells (Fig. 36). 
Consistent with what we observed in U2OS cells and mHCC 3-4 cells, BMAL1 mRNA is 
downregulated significantly and the oscillation is dampened in Shep N-MYC-ER (Fig. 33, 
35) and SKNAS N-MYC-ER (Fig. 34, 35) when N-MYC is induced. Similarly, PER2 is 
highly upregulated with high N-MYC in both cell lines (Fig. 34, 35). Furthermore, the 
expression of PER1, CRY1 and REV-ERBβ elevates in response to high N-MYC as 
expected (Fig. 34).  In contrast to robust Bmal1 transcript oscillation in parental Shep 
cells, where N-MYC is low, NLF and Kelly exhibit disrupted Bmal1 oscillation (Fig. 
36B). These observations further corroborate that in the presence of high N-MYC, 
upregulated REV-ERBα suppresses Bmal1 expression and oscillation. 
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High REV-ERBα and low BMAL1 associate with poor prognosis in neuroblastoma 
patients 
The increased REV-ERBα expression in response to high MYC has implied that 
upregulating REV-ERBα with consequently suppression of BMAL1 may have potential 
survival benefit for N-MYC-overexpressing tumor cells. To assess the relationship 
between expression of REV-ERBα and BMAL1 in the tumor samples and the associated 
patient outcome, we analyze the expression of REV-ERBα and BMAL1 in a 
neuroblastoma patient cohort. Tumors that are graded as high risk tend to have 
significantly higher REV-ERBα mRNA level and lower BMAL1 expression (Fig. 37D, 
37E). Consistent with previous studies, high N-MYC is linked to poor patient outcome 
(Chan et al., 1997). Surprisingly, tumors that express high NR1D1 (REV-ERBα, Fig. 37B) 
and low ARNTL (BMAL1, Fig 37C) are also correlated with poor prognosis. Furthermore, 
in a separate cohort with 476 neuroblastoma patients, patients who have neuroblastoma 
with NR1D1 (REV-ERBα) expression higher than median had poorer overall survival than 
did patients who had neuroblastoma with NR1D1 expression lower than median (Fig. 37 
F). Patients who had neuroblastoma with ARNTL (BMAL1) expression higher than 
median consistently live longer than those who had neuroblastoma with lower ARNTL 
expression (Fig. 37G). These data suggest that the suppression of BMAL1, most likely 
through upregulation of REV-ERBα, is critical for the growth of neuroblastoma both in 
cell culture and in patient samples.    
 
Colony suppression assay with BMAL1 overexpression 
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Since suppression of BMAL1 appears to be beneficial for the growth of neuroblastoma, 
we sought to determine whether BMAL1 has the ability to suppress tumor growth. To 
test this, we transiently transfect pCMV6-EV or pCMV6-ARNTL vector in human 
neuroblastoma cell line NLF and Kelly, where MYCN is amplified and BMAL1 
expression is normally low, and assess colony suppression. Elevated BMAL1 expression 
can be detected by immunoblot after transient transfection (Fig. 38A).  Interestingly, 
colony formation is greatly reduced in both cells with BMAL1 overexpression, indicating 




Our findings demonstrate that REV-ERBα is crucial for N-MYC-mediated BMAL1 
suppression, which in turns promotes tumor progression in human neuroblastoma. We 
provide evidence that elevated REV-ERBα expression is correlated with c-MYC-
overexpressed T-ALL as well as MYCN-amplified neuroblastoma. In addition, we found 
N-MYC directly upregulates REV-ERBα in N-MYC inducible cell line. Intriguingly, both 
high REV-ERBα expression and low BMAL1 expression predict poor prognosis of 
patients with neuroblastoma in two independent patient cohorts. Finally, constitutively 
overexpressed BMAL1 is sufficient to suppress colony formation in neuroblastoma cell 
lines. Overall, there is a solid link between loss of clock and cancer progression in N-
MYC driven neuroblastoma. 
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The first report implicated that REV-ERBα is a potential oncogene is done in breast 
cancer (Kourtidis et al., 2010). The gene encodes REV-ERBα, NR1D1, is located within 
17q12-21 amplicons that containing ERBB2. ERBB2 is overexpressed in approximately 
30% of breast cancers, suggesting upregulating REV-ERBα could exhibit in a broad 
breast cancer population (Kourtidis et al., 2010). REV-ERBα has been shown to promote 
fatty acid synthesis in these ERBB2-postive breast cancer cell lines (Kourtidis et al., 
2010). Interestingly, based on our observation that overexpression of BMAL1 suppress 
colony formation in neuroblastoma cell lines, we postulated that REV-ERBα-tumor 
promoting effect is largely from BMAL1 suppression. Recent study also supported our 
finding that the promoter of BMAL1 is epigenetically silenced in ovarian cancer cell lines 
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MYC orchestrates major cellular metabolic pathways, particularly enzymes that are 
involved in glycolysis, the TCA cycle, fatty acid synthesis and nucleotide synthesis 
(Hsieh et al., 2015; Stine et al., 2015). Given our observation that MYC disrupts 
molecular clock circuitry by upregulating REV-ERBs to suppress BMAL1 expression and 
oscillation, it stands to reason that the disruption of the molecular clock can affect 
metabolism. There are multiple pieces of evidence that lead to this hypothesis. First, as 
extensively reported, BMAL1 has a central role in regulating metabolism (Bass, 2012). 
Knockdown of BMAL1 leads to disrupted oscillation of metabolic processes (Kennaway 
et al., 2013). Since MYC suppresses BMAL1, the metabolic processes driven by the 
molecular clock are likely to be affected. Second, as discussed in Chapter 1, MYC 
induces the expression of key enzymes in the metabolic pathway by binding to the E-box 
within their promoters, which is the same site to which CLOCK::BMAL1 heterodimer 
binds to regulate its target genes(Yoshitane et al., 2014). The combination of high level 
of MYC and reduced level of BMAL1 may dramatically change the dynamic of 
transcription factor occupancy and gene expression as demonstrated from the observation 
of USF1 in Clock mutant mice (Shimomura et al., 2013). Third, rapid growing cells will 
require high metabolic activity to support their growth. Thus, releasing expression of 
rate-limiting enzymes from circadian control may be critical to maintain constant, 
heightened metabolic flux. 
In this chapter, we provide evidence that MYC reprograms metabolic processes in U2OS 
MYC-ER cells and alters the metabolic circadian profile. We also demonstrated that 
circadian glucose oscillation in MYC-OFF cells is disrupted by MYC, which in turns 
promotes rapid consumption of glucose, lactate, pyruvate, glutamine and glutamate for 
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biosynthesis. Finally, oscillation of phospho-AMPK, a surrogate of cellular energetics, is 
also disrupted by MYC.    
 
Material and Methods 
Plasmids 
 c-MYC-ER™ wt and Δ106-143, which are responsive to tamoxifen and 4-
hydroxytamoxifen but not to estrogen, were received in the pBabe-puro vector courtesy 
of Dr, Linda Penn, Ontario Cancer Institute, University Health Network, University of 
Toronto, Canada) and were described previously (Littlewood et al., 1995).  c-MYC-ER™ 
wt and Δ106-143 were subcloned into pBabe-Zeo (Morgenstern and Land, 1990) 
(courtesy of Dr. Robert Weinberg, Whitehead Institute for Biomedical Research, 
Cambridge, MA, USA, Addgene plasmid 1766).  Retrovirus was generated in 293T cells 
using the pCMV-VSVG and pUMVC vectors (Stewart et al., 2003) (courtesy of Dr. 
Robert Weinberg, Addgene plasmids 8449 and 8454). 
Cell Culture 
U2OS cells with BMAL1::luciferase vector were kindly shared by Dr. John 
Hogenesch (Baggs et al., 2009). U2OS cells were cultivated in Dulbecco’s modified 
Eagle’s medium (DMEM, Mediatech, Manassas, VA, USA, starting glucose 
concentration of 25 mM and starting glutamine concentration of 4 mM).  Media was 
supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA or Life 
Technologies, Grand Island, NY, USA) and 1X Penicillin/Streptomycin (Mediatech) for 
	   100	  
all cells. Some U2OS MYC-ER™ were treated with 500 nM 4-hydroxytamoxifen (Sigma, 
St. Louis, MO, USA) or ethanol control. 
For U2OS MYC-ER metabolomics, cells were plated three days prior to sample 
harvest and allowed to grow to confluence.  Two days before harvest, cells were treated + 
500 nM 4OHT (MYC-ON) or ethanol (MYC-OFF) (without changing media), and one 
day prior to harvest, cells were synchronized with 0.1 uM dexamethasone (without 
changing media).  During experiment, cells were collected every two hours by washing 
with cold PBS, scraping into a small volume of cold PBS, spinning down cells into a 
pellet, and snap-freezing.  At each timepoint, 1 mL of media was spun down to clear it of 
debris, and also snap frozen.  Pellets and media were extracted for NMR as described 
below. 
U2OS BMAL1::Luc cells were stably transduced with MYC-ER™, MYC-ER™ 
Δ106-143, or pBabe-Zeo empty vector retrovirus using the plasmids and methods 
described above.  Infected cells were selected for with 100 µg/ml Zeocin (Life 
Technologies) for two weeks, then continually cultured in Zeocin except during 
experiments. 
All cell culture, except that during live-cell luminometer experiments (see 
Lumicycle section below), was conducted in a 5% CO2 humidified atmosphere. 
Cell and media extraction for NMR analysis 
U2OS cell pellets were thawed on ice and extracted using a modified Bligh-Dyer 
method (Bligh and Dyer, 1959; Tambellini et al., 2013). Briefly, a methanol: chloroform 
(2:1) mixture (300µl) was added to cell pellets, then vortexed and sonicated for 15 min. 
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Chloroform and water (100µl each) was then added and samples were again vortexed. 
Organic and aqueous layers were partitioned by centrifugation at 13,300rpm, for 7mins at 
4°C. 100µl of the aqueous layer was dried in a speed vacuum for 4hrs until dry and 
immediately prepared for NMR analysis as described below. 
Media samples (50µl each) were centrifuged at 14000 rpm for 20 min, and the 
supernatant was prepared for NMR as described below.  Liquid chromatography-mass 
spectrometry (LC-MS) - grade Acetonitrile, Methanol, Chloroform was purchased from 
Fisher Scientific (New Jersey, USA). 
NMR Spectroscopy and Quantitative Profiling 
The samples were dissolved in 200 µl phosphate buffer (final pH ~7.1) containing 
Sodium-2,2-Dimethyl2-Silapentane-5-Sulfonate (DSS, Cambridge Isotope Limited, 
Andover, MA) (Cambridge Isotope Limited, Cambridge, UK 0.175 mM for media 
samples and 0.255 mM for cell samples) and 10% D2O for field frequency lock purpose 
(Cambridge Isotope Limited, Cambridge, UK). The samples were transferred to NMR 
tubes (3mm I.D, Bruker Biospin, Billerica, MA).  All NMR spectra were acquired on 
Avance III HD 700 MHz NMR spectrometer from Bruker Biospin (Billerica, MA) 
equipped with a 3mm NMR triple resonance inverse probe and SampleJet cooled to 10oC 
for automated spectral acquisition. 
For all 1-dimensional NMR spectra, the pulseprogram took the shape of first 
transient of a 2 dimensional NOESY and generally of the form RD-90-t-90-tm-90-ACQ. 
Where RD = relaxation delay, t = small time delay between pulses, tm = mixing time and 
ACQ = acquisition (Beckonert et al., 2007). The water signal was saturated using 
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continuous irradiation during RD and tm. The spectra were acquired using 76K data 
points and 14 ppm spectral width. 378 scans were performed and 1 second interscan 
(relaxation) delay and 0.1 second mixing time was allowed. The FIDs were zero filled to 
128K; 0.1 Hz of linear broadening was applied followed by Fourier transformation. 
NMR spectra were imported into Chenomx v 8.0. (Edmonton, Canada) for 
quantitative targeted profiling (Weljie et al., 2006). The processor module was used to 
phase and baseline correct the spectra followed by internal standard calibration and 
deletion of water region. The processed spectra were then imported to the profiler module 
for targeted profiling. Quantified data from this process were exported for further 
analysis. 
Principal Component Analysis of metabolites 
NMR spectra was profiled using Chenomx v8.0 (Edmonton, Canada) and the profiled 
data from all the spectra consisting of concentration values from the metabolites was used 
as the input dataset for Principal Component Analysis (PCA). PCA was performed in 
Simca-P 13.0 (Umetrics AB, Sweden). The data was mean centered and autoscaled prior 
to implementing the algorithm. Auto scaling was performed by dividing each variable by 
its standard deviation. The quality of the model was judged by the goodness of fit (R2) 
and goodness of prediction (Q2) based on a 1/7th round of cross-validation. 
Quantitative Analysis of Metabolite Oscillations  
Output concentrations from the NMR analysis were imported into the R statistical 
framework (Team, 2015), and were noted to have significant temporal change in overall 
concentrations. Thus a detrending algorithm was applied from the pracma R package 
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(Borchers, 2015) prior to assessment of rhythmicity in the metabolite data. Oscillations 
were assessed using the non-parametric JTK_CYCLE algorithm (Hughes et al., 2010), 
testing for period lengths between 22 and 26 hours corresponding to circadian events. 
The default cosine function was used to assess rhythmic patterns and tested against the 
experimental data as a function of both period length, phase and amplitude. Rhythms 
were considered significant if the Benjamini-Hochberg corrected false discovery rate 
(BH.Q) was < 0.05 (Benjamini and Hochberg, 1995). 
 
Results 
U2OS MYC-ER cells display distinct metabolites clustering between MYC-ON and 
MYC-OFF state 
After observing that elevated MYC suppresses the molecular clock in a number of 
different cell lines, we further sought to determine the functional impact on metabolism, 
particularly the major biological processes that have been previously documented to be 
regulated by circadian rhythm. To this end, we cultured U2OS MYC-ER cells in both 
MYC-ON and MYC-OFF states, synchronized them with dexamethasone and then 
harvested both the cell pellets and supernatant media every two hours. Metabolites from 
cell pellets and media were extracted and analyzed by nuclear magnetic resonance (NMR) 
spectroscopy. 
Principle component analysis (PCA) of all time points has revealed that despite the 
variance between time points, the overall clustering of MYC-ON and MYC-OFF cells are 
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very distinctive (Fig. 39). This observation is consistent with what has been reported in 
literature regarding rewiring of metabolism by oncogenic MYC (Dang, 2013). 
 
Oscillation of glucose metabolism is abolished in MYC-ON cells 
NMR spectroscopy allows us to observe selective metabolites in a quantitative way, 
including glucose, glutamine, pyruvate, lactate and glutamine. Each metabolite was 
measured over a 48-hour time course in 2-hour intervals, and the resulting metabolite 
concentrations as a function of time subjected to JTK analysis to evaluate the period and 
the robustness of oscillation. As expected, glucose level is greatly reduced in MYC-ON 
cells both in the cell and in the media, suggesting that MYC induces high flux of 
glycolysis (Fig. 40). Strikingly, intracellular glucose level in MYC-OFF cells exhibits a 
24-hour oscillation which has a p-value of 0.052 in JTK analysis (Fig. 40). This circadian 
oscillation, however, is dampened in MYC-ON cells (Fig. 40). Interestingly, glucose 
level also appears to oscillate in the media with the trough at 12 hour and 26 hour, 
matching with the timing of peak glucose level intracellularly (Fig. 40).  Low level of 
intracellular and extracellular glucose indicates that in addition to the molecular clock 
disruption, MYC also induces several glycolytic enzymes allowing cells to consume 
glucose rapidly, perhaps for macromolecular synthesis. End-products of glucose 
metabolism, such as pyruvate and lactate, also appears to oscillate in MYC-OFF cells 
(Fig. 40). The timing of the highest concentration of pyruvate and lactate correlates with 
the trough of intracellular glucose level (Fig. 40), suggesting BMAL1-controled glucose 
metabolism is affecting the entire glycolytic pathway. Pyruvate level decreased overtime  
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in the culture media of MYC-ON cells and was not detected intracellularly in both 
conditions, further indicating rapidly consumption for TCA cycle fueling and 
biosynthesis pathways (Fig. 40). Compared with gradual accumulation of lactate in 
MYC-OFF cells, lactate remains low in MYC-ON cells (Fig. 40). Low intracellular 
lactate is possibly a consequence of increased lactate export through MYC-mediated 
monocarboxylate transporter 1 (MCT1) overexpression (Doherty et al., 2014), which is 
further reflected by increased lactate accumulation in the culture media of MYC-ON cells 
(Fig. 40). Similarly, the level of glutamine within cells of both MYC states did not reach 
the detection threshold of NMR. Glutamine derived glutamate, however, was rapidly 
consumed in MYC-ON cells intracellularly and extracellularly (Fig. 40). Our 
observations suggest that both glutamine and glutamate were likely used for biosynthesis. 
Collectively, disruption of BMAL1 by MYC profoundly alters cellular metabolism, 
featured by enhanced glycolysis flux, which prepares cancer cells to fulfill metabolic 
demands required for rapid growth.   
 
MYC disrupts oscillation of AMPK phosphorylation 
Since glycolysis is the most important metabolic pathway to generate ATPs, changes in 
glycolytic flux can alter cellular energetic status. Given the observation that MYC 
disrupts normal oscillation of glucose metabolism, we next sought to determine the effect 
of circadian disruption by MYC on cellular energetics. We use phosphorylation of AMP-
activated protein kinase (AMPK) as a measure of cellular energetics. AMPK plays a 
critical role in maintaining cellular energy homeostasis (Hardie and Alessi, 2013). When  
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cells don’t have enough energy, ATP level will drop and AMP will accumulate. Elevated 
level of AMP promotes AMPK phosphorylation and activates it. Activated AMPK will 
suppress anabolic pathways that consume ATPs and induce catabolic pathways that 
generate ATPs. Interestingly, immunoblot showed phospho-AMPK peaks at 12 hours and 
40 hours in MYC-OFF cells, the exactly same time points when glucose level is highest 
in the cell (Fig. 41). When glucose level is high, less glucose was used and less ATPs 
were being generated. As a result, accumulation of AMP activates AMPK. However, the 
oscillation of phospho-AMPK is not evident in MYC-ON cells, where BMAL1 is greatly 
reduced (Fig. 41). This observation further demonstrates that loss of clock leads to 
enhanced glycolysis and increased cellular energetics. Hexokinase 1 (HK1), the first rate-
limiting enzyme of glycolysis, shows a slight oscillation in MYC-OFF cells (Fig. 41). 
However, in MYC-ON cells, hexokinase 2 (HK2) is dramatically induced and no 
oscillation is appreciable (Fig. 41). Once again, our data support that MYC concurrently 
suppresses clock-controlled glucose metabolism and activates MYC-induced glycolytic 
pathway, which results in heightened metabolism in tumor cells.  
 
MYC disrupts NAMPT and NAD+ oscillation 
Previous study has shown that NAMPT robustly oscillates every 24 hour in mouse liver 
and white adipose tissue (Nakahata et al., 2009; Ramsey et al., 2009). Its oscillation is 
abolished in Clock mutant mice, suggesting NAMPT is regulated by clock (Nakahata et 
al., 2009; Ramsey et al., 2009). Interestingly, NAMPT is also one of the canonical MYC 
target genes (Menssen et al., 2012). When we examine mRNA expression of NAMPT in  
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U2OS MYC-ER cells, NAMPT appears to oscillate with a period of 36 hour in MYC-
OFF cells (Fig. 42A). When MYC is induced, NAMPT transcript elevates and loses its 
oscillation (Fig 42A). NAMPT is the rate limiting enzyme in NAD+ salvage pathway and 
knockdown of NAMPT reduces NAD+ levels (Menssen et al., 2012). NAD+ is an 
important co-factor in many metabolic pathways, thus alteration of its level results in 
profound metabolic effects (Canto and Auwerx, 2011; Chiarugi et al., 2012; Hara et al., 
2007). We next examine whether disruption of NAMPT expression affects NAD+ levels 
from our circadian metabolomic experiment. Interestingly, NAD+ in MYC-OFF cells 
seems to oscillate approximately every 14 hour (Fig. 42B), which is similar to NAD+ 
oscillation in mouse liver that has been documented in the literature (Ramsey et al., 2009). 
In MYC-ON cells, however, intracellular NAD+ level dramatically increases and spikes 
up and down every 8-12 hour, consistent with the pattern of NAMPT transcript in MYC-
ON cells (Fig. 42B). In addition, Nampt mRNA oscillate robustly with a period 
approximately 24 hours in mHCC 3-4 c12 cells when MYC is off, but the oscillation is 
gone when MYC is induced (Fig. 42C). Collectively, here we showed that high MYC 
elevates and accelerates NAMPT oscillation, which leads to “ultradian” oscillating NAD+ 
levels in cancer cells. However, whether MYC-induced ultradian oscillation of NAD+ 
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Discussion 
Circadian rhythm synchronizes and regulates metabolism to ensure organismal fitness 
(Bass, 2012). Obesity, liver steatosis and other metabolic disorders often arise in animal 
models lacking the molecular clock regulators (Kennaway et al., 2013; Paschos et al., 
2012). In MYC-driven cancer cells, as we showed in previous chapters, molecular clock 
regulator BMAL1 is profoundly suppressed. As a result, we would surmise that clock-
controlled metabolism is similarly disrupted. Here, we have demonstrated that MYC 
indeed releases metabolism from circadian constraints and reprograms metabolic 
pathways to promote rapid growth. By using a high-resolution time course metabolomics 
analysis, we revealed that there is circadian oscillation of intracellular glucose level in 
synchronized U2OS cells. The oscillation, however, is eliminated when MYC is induced. 
MYC activation leads to hexokinase II elevation, which in turns increases glycolytic flux. 
Significant reduction of glutamine, glutamate, pyruvate and loss of pAMPK oscillation 
suggest that MYC-driven cells are undergoing biosynthesis. Overall, MYC’s ability to 
suppress BMAL1 provides a convenient metabolic switch from homeostasis to 
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We have observed that overexpressed MYC in mammalian cancer cells can suppress 
BMAL1 oscillation and expression through upregulating REV-ERBα. We sought to 
determine whether Drosophila Myc will alter the molecular clock in the similar way as 
mammalian cancer cells. Drosophila Myc (called dMyc) is a transcriptional factor that is 
highly conserved with functional properties similar to mammalian MYC, including 
regulation of cell growth, development, and metabolism (Demontis and Perrimon, 2009; 
Grewal et al., 2005). However, the role of dMyc in the Drosophila molecular clock and 
metabolism is not known. Drosophila is a great in vivo model for Myc disruption of 
circadian rhythm for the following reasons: First, Drosophila Myc has similar function 
and gene regulatory mechanism as mammalian MYC. Second, Drosophila exhibits well-
conserved molecular clock circuitry that resembles mammalian clock (Fig. 43). Finally, 
Drosophila exhibits robust circadian locomotor activity that is easy to monitor. 
In this chapter, we demonstrate that both gain-of-function and loss-of-function of dMyc 
can disturb circadian locomotor behavior in flies. Using the Drosophila Activity 
Monitoring system, we show that overexpression of dMyc specific in Pigment Dispersing 
Factor (PDF) and Cryptochrome (Cry) expressing cells results in a higher percentage of 
arrhythmic flies. In these flies, dMyc overexpression also induces several E-box 
containing genes, such as cycle (cyc), timeless (tim), cryptochrome (cry) and clockwork 
orange (cwo), however, the expression of Drosophila BMAL1 homolog clock (clk) was 
not altered. Morphological analysis of neurons required for circadian locomotor behavior 
in the dMyc-overexpressing flies showed decreased PDF staining in the dorsal projection 
while the cell bodies remain unchanged. Preliminary metabolic profiling of the heads 
from these flies using GC-MS revealed that high dMyc leads to significant consumption  
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of valine and leucine, accompanied with accumulation of urea. Whether molecular clock 
perturbation or metabolic alteration resulting from high dMyc is the underlying 
mechanism of locomotor arrhythmicity requires further investigation. 
Interestingly, adult dMyc hypomorph flies also display higher percentage of arrhythmic 
circadian activity, which can be rescued by additional deletion of dMnt, a known 
suppressor of dMyc activity. In contrast to dMyc overexpression, loss of dMyc does not 
alter the mRNA expression and oscillation of clock-controlled genes. However, Per 
staining in small lateral ventral neurons (sLNvs), the central clock cells in Drosophila, is 
dramatically diminished specifically in arrhythmic dMyc hypomorph flies. Reduced Per 
staining in sLNvs of arrhythmic dMyc mutant flies is not observed in dMyc mutant flies 
with dMnt deletion, suggesting endogenous dMyc activity is essential for circadian 
behavior. Our results have demonstrated a novel role of dMyc in modulating Drosophila 
circadian locomotor behavior potentially through directly regulating components of the 
core molecular clock as well as an indirect effect on metabolism. 
 
Materials and Methods 
Fly stocks 
pdf-Gal4, tim-UAS-Gal4, tim-Gal4, cry24-Gal4 and dmP0 lines were provided by the 
Bloomington Stock Center. UAS-Myc UAS-p35 and dm4 were kindly shared by Dr. Julie 
Secombe (Albert Einstein College of Medicine, NY). dm4dmnt1 were provided by Dr.	  
Robert N. Eisenman (Fred Hutchinson Cancer Research Center). dm4 and dm4dmnt1 line 
were balanced with FM7i, Act-GFP. pdf-Gal4; cry24-Gal4 lines were generated from 
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crossing pdf-Gal4 to cry24-Gal4. dmP/Y and its sibling control w/Y were generated by 
backcrossed dmP0 line from Bloomington Stock Center with isogenic wild type line 
(wISO31). Flies that used for the experiments were grown at 25 ºC. 
Locomotor activity assay  
Circadian locomotor activity assays were measured using the Drosophila Activity 
Monitoring System (Trikinetics). Approximately 5- to 7-day-old adult flies were 
entrained to light-dark (LD) 12 hour: 12 hour (12:12) cycles for three days, then 
transferred to constant darkness (DD) for 7-8 days. Collected activity data were analyzed 
using Clocklab software (ActiMetrics). Individual periods were calculated from 7-8 days 
activity data during DD using chi-square periodogram. Rhythm strength was determined 
by FFT analysis, then categorized as arrhythmic (<0.01), weakly rhythmic (0.01-0.03) 
and rhythmic (>0.05). Periods and rhythm strength were only calculated from rhythmic 
and weakly rhythmic flies. 
Immunohistochemistry 
Five-day-old adult flies were entrained to LD 12:12 cycle for 3 days and then transferred 
to DD. Brain dissection were done on day 4 or day 5 in DD. Five to ten brains of each 
genotype at each time point were stained. Adult fly brains were dissected and fixed for 
30-60 min in 4% formaldehyde made in PBS with 0.3% Triton-X (PBST). Fixed brains 
were quickly rinsed twice in PBST, washed 3 x 10 min with PBST, followed by blocking 
with 5% normal donkey serum in PBST (NDST) for 1 hour. Brains were then incubated 
with primary antibody diluted in NDST at 4 ºC overnight. Brain samples were then 
washed 3 x 10 min with PBST, incubated with secondary antibody diluted in NDST at 
	   118	  
room temperature for 2 hours, washed with 3 x 10 min PBST again and mounted with 
Vectashield. A Leica TCS SP5 confocal microscope was used to acquire images for 
immunostained brain. Primary antibodies used include: rabbit anti-PDF (kindly shared by 
Dr. Amita Sehgal) and Guinea Pig anti-Per (kindly shared by Dr. Amita Sehgal). 
Secondary antibodies used include: Alexa-Flour 448 goat anti-rabbit IgG (Life 
Technologies), Alexa-Flour 448 goat anti-Guinea Pig IgG (Life Technologies), Cy3 
donkey anti-rabbit (Jackson ImmunoResearch Laboratories, West Grove, PA), Cy3 
donkey anti-mouse (Jackson ImmunoResearch Laboratories) 
Quantitative real-time PCR 
Five- to Seven- day old adult flies were entrained to LD 12:12 cycle for 3-5 days. 
Approximately 20 flies were collected on dry ice at each time points on the last day of 
LD. Adult fly heads were homogenized in TRIzol® Reagent using VMR Pellet Mixers 
for 10 sec. Total RNA was then extracted according to manufacturer’s instruction 
(TRIzol; Life Technologies) and reversed to complementary DNA by using TaqMan 
Reverse Transcription Reagents (Life Technologies).  cDNA was used as template to 
proceed to quantitative real time PCR (RT-PCR) with specific Drosophila primers. RT-
PCRs were performed using the ViiA™ 7 Real-time PCR system with a SYBR Green kit 
(Life Technologies). Relative mRNA expression levels were normalized to actin and 
analyzed using absolute quantification method. Standard curve used for quantification 
was determined by serial dilution of mixed samples from all time points. Primers used in 
the experiments were dMyc forward (5’-GAGCAACAACAGGCCATCGATATAG-3’), 
dMyc reverse (5’-CCTTCAGACTGGATCGTTTGCG-3’), per forward (5’-
CGTCAATCCATGGTCCCG-3’),	  per reverse (5’-CCTGAAAGACGCGATGGTG-3’), 
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tim forward (5’-GCTGCGCCTTGTTTTCCTT-3’), tim reverse (5’-
ATGATGTTCAGATCCTGCTGGA-3’), pdp forward (5’-
TTTGAACAGCTTGAAAGCGC-3’), pdp reverse (5’-
GAGATTTCCTGCCTGAGCTGG-3’), vri forward (5’-
CGACTCTCTCGATGAACGGC-3’), vri reverse (5’-
ACGGATGCAAGTTAGAAGCCTC-3’), actin forward (5’-
GCGCGGTTACTCTTTCACCA-3’), actin reverse (5’-
ATGTCACGGACGATTTCACG-3’), cry forward (5’-
GCAGTACGTCCCGGAGTTGA-3’), cry reverse (5’-
AGGGCTCGTGAACAAATTCCT-3’), clk forward (5’-
TTCTCGATGGTGTTCTCGGTG-3’), clk reverse (5’-AGTTCGCAAAGCCAACGG-3’), 
cyc forward (5’-GTACGTTTCCGATTCGGTGT-3’), cyc reverse (5’-
CTCTGTGGAACGTCGGTCTT-3’), cwo forward (5’-
CAGGACTTTTGCCACCGACTATTG-3’), cwo reverse (5’-
CTGCCGCCGCCTGCTGAC-3’), E75-PA forward (5’-
CGGTAATCTGCACATTGTCGC-3’), E75-PA reverse (5’-
TGCTTCAGCTGTTGGCTCTTG-3’), E75-PB forward (5’-
TGCAACATCATCCGGAGGAT-3’), E75-PB reverse (5'- 
TCCTCCAGATGCAGCATCTCA-3’), E75-PC forward (5'-
GACTTCTGTGATCTGCAGCACG-3’), E75-PC reverse (5'-
CGACCTGTTACCCCCAAAATG-3’), E75-PD forward (5'- 
GCGAAGAACTCCCGATATTGAA-3’), E75-PD reverse (5'- 
TGAACTCACAGGTCTCGAGGTG-3’) 
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Western blot analysis 
Five- to Seven- day old adult flies were entrained to LD 12:12 cycle for 3-5 days. 
Approximately 8-10 flies were collected on dry ice at each time points on the last day of 
LD. Adult fly heads were lysed and homogenized in 1X Passive Lysis Buffer (Promega) 
diluted in PBS supplemented with protease inhibitors and phosphatase inhibitor okadaic 
acid. Sample buffer (Thermo Cat:39000) was added to each sample. All samples were 
then boiled and spinned. Equaled-volume of supernatant from each sample was loaded 
into the Criterion pre-cast gradient gels (Bio-Rad, Hercules, CA, USA). Proteins were 
transferred onto nitrocellulose membranes using iBlot® Gel transfer system (Thermo). 
Primary antibodies used include: mouse anti-dMyc (kindly shared by Dr. Robert N. 
Eisenman), rabbit anti-α-Tubulin (Cell Signaling, Danvers, MA, USA) and Guinea Pig 
anti-Per (kindly shared by Dr. Amita Sehgal). Secondary antibodies used include: 
Peroxidase AffiniPure Goat Anti-Guinea Pig IgG (Jackson ImmunoResearch 
Laboratories), Goat anti-Mouse IgG1, HRP conjugate (Thermo). Immunoblots were then 
developed using ECL substrate (Thermo). 
Results 
Overexpressed dMyc affects circadian locomotor activity in a cell-specific manner 
To study the effect of dMyc overexpression on the Drosophila molecular clock, we took 
advantage of the well-establish Drosophila GAL4/UAS (upstream activating sequence) 
system. This system allows us to ectopically express transgene in a specific cell type and 
requires two transgenic fly lines. In the “driver” fly line, the yeast transcriptional 
activator GAL4 is placed downstream of a cell-specific promoter. In the “UAS-transgene 
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fly” line, the transgene is placed downstream of a UAS activation domain that containing 
GAL4-binding sites. The otherwise silent transgene is activated in the progeny of UAS-
transgene flies crossed to the “driver” flies that express GAL4. By using this system, we 
overexpress dMyc specifically in clock cells and observe the changes in circadian 
locomotor behavior to assess the effect of dMyc on the molecular clock in flies. Known 
clock-cell specific drivers including pdf-Gal4, tim-UAS-Gal4 and tim-Gal4 are used to 
cross with either isogenic wild type (wISO31,+) , UAS-p35 (p35) or UAS-dMyc UAS-p35 
(Myc+p35) flies. p35 is Drosophila homolog of BCL2, which has been documented 
previously to rescue overexpressed dMyc-induced life span shortening (Greer et al., 
2013). Overexpressing both dMyc and p35 allows us to observe the effects of dMyc on 
the molecular clock without the confounding cell apoptotic effect that introduced of 
dMyc overexpression alone (Greer et al., 2013).  
To assess the circadian locomotor behavior of these flies, we use the Drosophila 
Actogram Monitoring system. Each fly was loaded into a single glass tube and placed in 
a monitor housed in an incubator with controlled light/dark or dark/dark schedules. An 
infrared beam directed across the tube allows computers connected to the monitors to 
record every time when the fly interrupts the beam. The collected data is then plotted on 
actograms, which displayed the activities of a single fly over several days (Fig. 44A, C, 
E). 
We first overexpressed dMyc with use of the pdf-Gal4 driver, which is expressed only in 
ventral lateral neurons that are critical for circadian behavior. Pdf-Gal4-mediated dMyc 
overexpression leads to decreased percentage of rhythmic flies from 100% to 87% and 
decreased rhythm strength in rhythmic flies (Table 3, Fig 44A, B). Since Pdf-Gal4  
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expression is very limited, we subsequently used the tim-UAS-Gal4 (TUG) (Blau and 
Young, 1999) to expresses dMyc in other clock cells in addition to ventral lateral neurons. 
This TUG driver line has 5 UAS sites upstream of the transcription start site of tim 
promoter, so that Gal4 proteins produced downstream of tim promoter would positively 
regulate its own expression to diminish oscillatory tim promoter activity. However, 
overexpression of dMyc by TUG did not have any effect on either the period length or 
rhythm strength (Table 3 Fig. 44E, F). To express dMyc more broadly and at a higher 
level, tim-Gal4 driver was used. Overexpression of dMyc by tim-Gal4 causes a nearly 
200- to 500-fold increase in dMyc transcripts in fly heads that peak at ZT 18, consistent 
with the peak expression of timeless transcript (Fig. 45) (Sehgal et al., 1995). Western 
blot also showed significantly increased dMyc protein in tim-Gal4> UAS-Myc+p35 flies 
compare to Gal4 or UAS controls (Fig. 45). Broader expression of dMyc by tim-Gal4 
resulted in lower percentage of rhythmic flies (30%) compare to Gal4 control (56%) 
(Table 3, Fig. 44C, D). Notably, overexpression of dMyc by both TUG and tim-Gal4 
shortens period length significantly, suggesting a possibility that Per expression might be 
affected by high level of dMyc since mutation of Per alters the period of circadian 
locomotor activity (Konopka and Benzer, 1971). Interestingly, use of both Cry24-Gal4 
and Pdf-Gal4 driving dMyc expression (Cry24Pdf-G>Myc+p35) in ventral lateral 
neurons as well as Cry-expressing cells resulted in loss of rhythm in about 70% of the 
flies and weaker rhythm in the rhythmic flies (Table 3, Fig. 46A). These observations 
indicate that dMyc indeed affects Drosophila circadian behavior; however, the severity of 
perturbation on Drosophila circadian behavior appears to not correlate with the level of 
dMyc overexpression but instead where dMyc is expressed. 
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Overexpressed dMyc induces negative regulators but does not suppress clk 
To delineate the underlying mechanism of dMyc-mediated behavior perturbation, we first 
examined transcript levels of genes involved in the molecular clock in whole head 
extracts of tim-Gal4> UAS-Myc+p35 flies compared to Gal4 control flies. Consistent 
with what we observed in mammalian cancer cells (Fig. 9 and 16), dMyc induces most of 
the negative regulators, including per, tim, vri and cwo (Fig. 47A). Western blot from 
whole head lysates also demonstrated a significant increase in Per protein levels (Fig. 
47B). However, clk mRNA is not suppressed but slightly induced by dMyc in these flies 
(Fig. 47A). Similarly, mRNA of tim, cry and cwo are induced in Cry24Pdf-G>Myc+p35 
flies compare to control and clk is also not suppressed (Fig. 48). Our findings support the 
idea that dMyc indeed affects the molecular clock components in flies, however, 
Drosophila clk appears to be more resistant to dMyc overexpression than its homolog in 
mammalian cancer cells. 
In Chapter 3, we provide evidence that MYC suppresses BMAL1 through upregulation of 
REV-ERBα. Interestingly, Drosophila REV-ERBα homolog E75 has recently been 
identified and observed to analogously suppress clk (Kumar et al., 2014). We sought to 
determine whether dMyc regulates E75 in flies by examining the mRNA levels of all four 
isoforms of E75. To our surprise, transcript levels of all isoforms of E75 are unchanged 
in Cry24Pdf-G>Myc+p35 flies compared to control (Fig. 49), suggesting that MYC-
REV-ERBα-BMAL1 regulation that we observed in mammalian cancer cells is not 
conserved in Drosophila. 
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dMyc overexpressing flies showed shortening of PDF dorsal projection 
The minor change of clk mRNA expression upon dMyc overexpression is insufficient to 
explain the dramatically increased arrhythmicity that we observed in Cry24Pdf-
G>Myc+p35 flies. Since dMyc affects cell growth and apoptosis, we next examined the 
morphology of the ventral lateral neurons, which can be visualized by PDF staining 
through immunohistochemistry (IHC) of fly brain. While there is no gross abnormalities 
of the cell bodies of both large ventral lateral neurons (l-LNvs) and small ventral lateral 
neurons (s-LNvs), we noted shortening of the dorsal projections (Fig. 50, arrows) from s-
LNvs in Cry24Pdf-G>Myc+p35 flies compare to control (Fig. 50).  Interestingly, 
shortening of the dorsal projections from sLNvs has been observed in both clk mutant 
flies and cyc mutant flies (Park et al., 2000), suggesting Clk-mediated PDF expression or 
clock neuron development is likely to be affected in these flies. We also assayed Per 
protein expression in fly brain, however, no difference in Per protein expression was 
observed (Fig. 50) 
 
dMyc overexpression does not affect axonal development 
To further investigate whether the shortening of the dorsal projections from sLNvs is due 
to defects of axonal development, we took advantage of the marker UAS-mCD8-GFP, 
which is a fusion protein of mouse lymphocyte marker CD8 and the green fluorescence 
protein (GFP) (Lee and Luo, 1999). Since mCD8 is a transmembrane protein, it labels the 
cell surface, particularly axons and dendrites due to their high surface area. Recombining 
UAS-mCD8-GFP with either UAS-p35 or UAS-Myc;UAS-p35 flies and then crossing  
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with Cry24Pdf-G drivers allows us to visualize neuronal processes of Cry and Pdf 
expressing cells in dMyc overexpressing flies versus control flies. Consistent with our 
IHC data, Cry24Pdf-G>Myc+p35 flies exhibit shorter dorsal projections from sLNvs 
with less intense PDF staining (Fig. 51). In contrast, we found that there is no difference 
in abundance of mCD8-labeling axons/dendrites (Fig. 51, white rectangle), suggesting 
dMyc overexpression does not affect overall axonal development from Cry and Pdf 
expressing cells, instead, specifically reduce PDF staining at the dorsal projections.  
 
Overexpressed dMyc alters metabolism in fly head 
As mentioned in Chapter 1, MYC orchestrates a number of metabolic pathways. In 
addition, alteration of cellular energetic status, such as the ratio of NAD+/NADH or 
ATP/AMP was shown to feed back to the circadian clock (Lamia et al., 2009; Rutter et 
al., 2001). We thus hypothesized that overexpression dMyc by Cry24Pdf-Gal4 alters 
metabolism in fly heads, which in turns contributes to increased arrhythmic behavior in 
these flies. Cry24Pdf-G>Myc+p35 and control flies were snapfrozen in dry ice at 
different Zeitgeber Times after entrainment. Polar metabolites in fly heads were extracted 
by methanol-chloroform, derivatized by MTBSTFA and analyzed by gas chromatography 
mass spectrometry (GC-MS). While the majority of amino acids do not change with 
dMyc overexpression, we noted that the concentration of valine, leucine and glutamine is 
significantly reduced (Fig. 52). In addition, significant increase of urea (3-5 folds) and 
acetic acid is observed in Cry24Pdf-G>Myc+p35 flies compare to control (Fig. 52). The 
observations support the idea that dMyc plays a previously unknown role in regulating  
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metabolism despite the fact that its expression is limited to Cry- and Pdf- expressing cells. 
However, further investigations are required to determine whether this alteration of 
metabolism mediates dMyc-induced arrhythmic behavior in flies. 
 
Hypomorphic dMyc flies exhibit arrhythmic behavior 
As we mentioned in previous chapters, an earlier study documented that endogenous 
mouse Myc exhibits circadian expression that is regulated by Per2 (Fu et al., 2002). Loss 
of Per2 in mouse leads to loss of Myc oscillation, which eventually leads to 
tumorigenesis (Fu et al., 2002). But how endogenous MYC affects circadian clock 
remains poorly understood. Loss of dMyc has been associated with small body size; 
however, little is known about whether dMyc is indispensable for circadian behavior. To 
study whether loss of dMyc affects Drosophila circadian locomotor behavior, we took 
advantage of several available dMyc mutants, including the the hypomorphic Myc fly 
(dmP0, a result of insertion of a P-element within 100bp upstream of the transcription start 
site of dMyc) and a Myc null fly (dm4, a result of deletion of the first two exons) (Fig. 
53A) (Pierce et al. 2004, Development). dmP0/Y flies are viable but exhibit smaller body 
size (Fig. 53B) compare to its sibling control w/Y, however, dm4 flies are lethal at early 
larva stage (Johnston et al., 1999). When we assayed the circadian locomotor behavior of 
dmP0/Y compare to its sibling control w/Y, we found that while control flies exhibit 
robust circadian locomotor behavior, hypomorphic Myc flies displayed bimodal 
distribution in rhythmicity where about a third of flies were rhythmic, a third of flies were 
arrhythmic and the rest of flies were weakly rhythmic (Fig. 53C). Even among the  
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rhythmic dmP0/Y flies, rhythm strength also significantly decreased compare to sibling 
controls (Fig. 53E). 
 
dMnt mutation rescues arrhythmicity of dMyc mutant flies 
To verify the arrhythmic behavior in dmP0/Y flies is due to lower dMyc activity, we 
sought to determine whether mutation of the dMyc repressor Drosophila Mnt in dMyc 
mutant background is able to rescue the arrhythmic phenotype. Drosophila Mnt (dMnt) is 
a homolog of mammalian MNT and is a member of the Mxd family. Mnt and other 
members in the Mxd family antagonize Myc function by dimerizing with Myc-binding 
partner Max and recruit mSin3 co-repressor (Hooker and Hurlin, 2006). The E-box 
within the promoter of a canonical Myc target gene ornithine decarboxylase (Odc) is 
bound by Mnt-Max complex in quiescent cells but is occupied by Myc-Max complex 
instead in proliferating cells (Nilsson et al., 2004). Knockdown Mnt using shRNA has 
been shown to accelerate cell proliferation even in Myc-null cells (Nilsson et al., 2004). 
Loss of dMnt in dMyc-null flies is also able to rescue growth arrest from the early larval 
stage to pupal stage (Pierce et al., 2008). These published data support a model in which 
Mnt-Max complex normally binds and represses Myc target genes and this repression can 
be relieved by overexpressing Myc or loss of Mnt.  
Because dm4/Y and dm4dmnt1/Y cannot form adult flies, we crossed dMyc male 
hypomorph flies (dmP0/Y) with wild type female (WISO31), dMyc null female (dm4/FM7) 
and dMyc null female with dMnt mutation (dm4dmnt1/FM7) to generate female 
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heterozygotes dmP0/+, dmP0/dm4 and dmP0/dm4dmnt1, respectively.  dMyc transcripts 
increase about 3-fold in fly heads from dmP0/+ flies compared with dmP0/dm4 flies (Fig. 
54A). Unlike overexpressed dMyc protein, endogenous dMyc protein was not detectable 
either in fly heads from dmP0 or dmP0/ dm4 flies with the anti-dMyc antibody (Fig. 54B). 
To determine the effects of the varying degrees of Myc activity possessed by our flies, we 
next examined their circadian locomotor behavior in these in constant darkness after 
entrainment. As expected, dmP0/dm4 flies exhibit significantly reduced rhythmicity 
compare to dmP0/Y flies (30% versus 94%) (Fig. 55A). Similar to dMyc hypormorphic 
dmP0/Y flies, dmP0/dm4 flies exhibit bimodal distribution of rhythmicity where 47% of 
flies are arrhythmic while 30% of flies remain rhythmic (Fig. 55A). Strikingly, dMnt 
mutation in dm4 background reduced the arrhythmicity from 47% down to 7% (Fig. 55A). 
There is no difference in period length between three female heterozygotes but rhythm 
strength of rhythmic flies is significantly reduced in dmP0/dm4 flies and rescued in dmP0/ 
dm4dmnt1 flies (Fig. 55C, D). 
 
Molecular clock is not affected in dMyc mutant flies  
To explore the underlying mechanism of arrhythmic behavior in dmP0/dm4 flies, we first 
examined whether the transcripts levels of circadian clock components are altered in 
these flies. Interesting, despite a two-third reduction in dMyc mRNA expressed in the 
heads of dmP0/dm4 flies (both rhythmic and arrhythmic flies), the mRNA level of most 
molecular clock components is not changed (Fig. 56). Since overexpressed dMyc 
elevates PER protein level (Fig. 47), we further assayed PER level by western blot in  
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dmP0/+ and dmP0/dm4 flies. However, there are no significant difference in PER protein 
expression between dmP0/+ and dmP0/dm4 flies (Fig. 57). Together, these results suggest 
that molecular clock expression is not affected in dmP0/dm4 flies compare to dmP0/+ 
control.  
 
Loss of dMyc resulted in reduced sLNv Per expression in arrhythmic hypomorphic 
flies 
As mentioned before, ventral lateral neurons are central clock cells in Drosophila that are 
crucial for maintaining rhythmic behavior in constant darkness. To investigate whether 
the clock protein oscillation is indeed unaffected in ventral lateral neurons, particularly in 
those arrhythmic flies, we compare PER protein in dissected fly brain from dmP0/+, 
dmP0/dm4 rhythmic, dmP0/dm4 arrhythmic and dmP0/dm4dmnt1 flies using 
immunohistochemistry. We focused on small ventral lateral neurons (sLNvs), because 
their Per expression is cyclic with nuclear Per expression reaching its peak at CT2 and 
minimum at CT14. At CT2, nuclear Per accumulation in sLNvs was dramatically reduced 
in arrhythmic dmP0/dm4 flies but not in rhythmic dmP0/dm4 flies relative to dmP0/+ flies 
(Fig. 58). The reduced Per nuclear accumulation was also rescued in dmP0/dm4dmnt1 flies 
(Fig. 58). We noticed similar pattern at CT20, where pan-cellular Per expression is the 
lowest in arrhythmic dmP0/dm4 flies compare to its rhythmic dmP0/dm4 siblings, dmP0/+ 
and dmP0/dm4dmnt1, suggesting that the decreased Per nuclear accumulation at CT2 in 
arrhythmic dmP0/dm4 is not due to asynchrony, but overall decrease in Per expression at  
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all time points. Our data therefore support that loss of dMyc attenuates Per expression in 
sLNvs in a subset of flies, contributing to their arrhythmic behavior. 
 
Discussion 
Many crucial functions of Myc are well-conserved in Drosophila, including regulation of 
growth, cell size and metabolism (Gallant, 2013). Myc’s interaction with other members 
in the Myc family remains critical in target gene regulation, including its antagonism by 
dMnt (Pierce et al., 2008). In this chapter, we provide evidence that Drosophila Myc 
(dMyc) also plays a role in modulating circadian locomotor behavior in flies. We showed 
that overexpressing Myc in clock cells using Pdf-Gal4, tim-UAS-Gal4 and tim-Gal4 
generally causes decrease of rhythm strength in rhythmic flies. Overexpressed dMyc 
induces mRNA level of several negative regulators and also induces PER protein 
expression. However, unlike Myc overexpression in mammalian cancer cells, 
overexpressed dMyc did not suppress Drosophila clk mRNA expression. We noticed that 
overexpressing dMyc specific in Pdf and Cry expressing cells resulted in loss of rhythm 
in more than 30% of flies. Although clk transcript level was not significantly altered in 
these flies, morphological analysis showed significant reduction of PDF expression in the 
dorsal projections from sLNvs, suggesting the molecular clock output PDF is affected by 
overexpressed dMyc. In addition, metabolomics analysis showed decrease of valine, 
leucine and glutamine and an increase in urea and acetate levels in heads of Cry24Pdf-
G>Myc+p35 flies compare to controls. Together, our data indicated that overexpressed 
dMyc affects drosophila circadian behavior through both direct regulation of the 
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molecular clock expression as well as indirect regulation of clock output PDF and 
metabolite levels that feedback upon the clock.  
Unlike the molecular clock in mammalian cancer cells suppressed by overexpressing 
Myc shown in Chapter 3, Drosophila circadian clock appears to be relatively resistant to 
elevated dMyc level. With over 200 to 500-fold dMyc transcript and significant elevation 
of dMyc protein in tim-G>Myc+p35 flies, the percentage of rhythmic flies only drops 
from 56% to 30%. Cry24Pdf-G>Myc+p35 flies showed a severely arrhythmic phenotype; 
however, dMyc transcript was only 3 folds higher than controls, suggesting dMyc-
mediated disruption of circadian behavior in flies is dependent on where dMyc is 
expressed rather than on how much dMyc is expressed. The differences in consequences 
of Myc overexpression in cancer cells and Drosophila could be due to compensation and 
intact antagonistic regulation occurring in the whole organism.  
The metabolic alteration we observed in Cry24Pdf-G>Myc+p35 flies is very interesting. 
With limited dMyc expression in specific cell groups, the reduction in valine, leucine and 
the accumulation of urea is surprising in its magnitude. A recent study observed a 
dramatically reduction of BCAA, particularly valine and leucine, in Arginase (Arg1)-
deficient mice (Sin et al., 2013). Arginase is a rate-limiting enzyme in urea cycle, 
converting arginine to ornithine and urea. Correspondingly, Arg1-deficient mice exhibit 
hyperargininemia and hyperammonia. Although we did not observe hyperargininemia 
and hyperammonia in our fly heads, the accumulation of urea in fly heads suggests high 
urea cycle flux. However, further investigation is required to determine whether this 
metabolic alteration is correlated with loss of rhythm in Cry24Pdf-G>Myc+p35 flies.  
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Although overexpressing dMyc does not seem to recapitulate overexpressing mammalian 
MYC in cancer cells, our observation of increased arrhythmicity in dMyc mutant flies 
suggests that endogenous dMyc is critical for maintaining rhythmic behavior. Loss of Per 
expression in arrhythmic dMyc hypomorph flies suggest endogenous dMyc may serve to 
maintaining basal level of Per expression, the loss of which results in arrhythmic 
behavior (Konopka and Benzer, 1971). Interestingly, loss of dMyc does not ablate either 
rhythmicity or Per expression in all progenies, instead, we observe a dichotomous 
distribution of rhythmicity as well as Per expression. We speculate that normally dMyc is 
responsible for maintaining Per level that is sufficient to maintain rhythmic behavior. 
However, in dMyc mutant flies, low dMyc level fails to maintain Per level and Per 
expression level and rhythmicity is thereby determined by other factors. The observation 
of biphasic response of E2F to low level Myc induction from a recent study shed a light 
on this underappreciated gene regulation by MYC (Wong et al., 2011). In this study, 
single cell measurement of viral-mediated MYC overexpression showed that full 
activation of E2F only occurs within a very narrow range of Myc level. However, a broad 
distribution of E2F response occurs when MYC level is either too high or too low. We 
suspect that in dMyc mutant fly, there is a possible biphasic response of Per, which in 
turns lead to a dichotomous distribution of rhythmicity. However, further studies are 
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Annie L. Hsieh, MD 2400 Chestnut St. APT 1711, Philadelphia, PA 19103 (410) 812-3083   ahsieh@mail.med.upenn.edu 
U.S. citizen  
Place of Birth: Gaithersburg, MD 
 
EDUCATION                                                                                                                                         
Johns Hopkins University School of Medicine, Pathobiology, Ph.D. Candidate 8/2010-Present 
Johns Hopkins Bloomberg School of Public Health, Certificate in Health Finance & Management 9/2010-5/2013 
Tzu Chi University College of Medicine, Doctor of Medicine, GPA: 3.82, Rank in Class = 3/56 9/2003-6/2010 
 
RESEARCH EXPERIENCE                                                                                 
University of Pennsylvania, Perelman School of Medicine, Abramson Cancer Center 
Advisor: Chi V. Dang, M.D, Ph.D. 
Study: Investigate the disruption of the circadian clock and metabolism caused by overexpressed oncogene 
MYC in cancer cells.  
!! Designed and performed experiments, acquired new techniques and wrote manuscript. 
!! Engineered mouse hepatocellular carcinoma cell lines with clock reporter to assess the recovery of 
circadian clock upon inactivation of MYC 
!! Developed colony suppression assay to clarify the role of a clock component (Bmal1) as a tumor 
suppressor 
!! Peer-reviewed Publication: Altman, BJ*, Hsieh, AL*, Sengupta, A, Krishnanaiah SY, Stine, ZE, Walton 
ZE, Gouw, AM, Venkataraman, A, Li, B, Goraksha-Hicks, P, Diskin, SJ, Dellovin, DI, Simon, MC, 
Rathmell, JC, Lazar, MA, Maris, JM, Felsher, DW, Hogenesch, JB, Weljie AM, Dang CV. MYC disrupts 
the circadian clock and metabolism in cancer cells Cell Metabolism In press. *Co-first authors. 
!! Oral presentation: Keystone Symposia: Molecular Clockworks and the Regulation of Cardio-Metabolic 
Function, 2013 
!! Poster presentation: Annual Society for Neuro-Oncology Scientific meeting, 2014; American Association 
of Cancer Research annual meeting, 2014, ASCI/AAP joint meeting, 2011 
8/2011-
Present 
Howard Hughes Medical Institute, University of Pennsylvania, Department of Neuroscience 
Advisor: Amita Sehgal, Ph.D. and Chi V. Dang, M.D., Ph.D. 
Study: Investigate the role of Drosophila Myc in affecting circadian locomotor behavior in fruit flies. 
!! Initiated collaboration, designed and executed experiments. 
!! Developed method using mass spectrometry to analyze metabolomics of fly heads. 
!! Used drosophila activity monitors to assess circadian behavior of flies with overexpressed or 
hypomorphic Myc 




Johns Hopkins University, Department of Neuroscience, Department of Pathology 
Advisor: Philip C. Wong, Ph.D. 
Study: Examine transactive response DNA-binding protein 43 (TDP-43) gene function in myoblasts. 
!! Performed myoblast culture and developed glucose consumption measurement to assess metabolic 
alteration of myoblasts harboring TDP-43 mutation. 
12/2010-
2/2011 
Johns Hopkins University, Department of Neuroscience, Department of Pathology 
Advisor: Lee J. Martin, Ph.D. 
Study: Investigate mitochondriopathy in superoxide dismutase 1(SOD1) mutated amyotrophic lateral 
sclerosis. 





TEACHING EXPERIENCE                                                         





Basic Medical Mandarin, Johns Hopkins University School of Medicine, Instructor 
!! Initiated and lectured Basic Medical Mandar in Course for  medical and nur sing students.  
!! Designed cour se mater ial with interactive activities to familiar ize students with symptomatic 
and diagnostic terms in Mandar in. Aimed to facilitate students’ communication with 
Mandar in-speaking patients. 
2011 
 
PUBLICATIONS                                                                                            
!! Altman, BJ*, Hsieh, AL*, Sengupta, A, Krishnanaiah SY, Stine, ZE, Walton ZE, Gouw, AM, Venkataraman, A, Li, 
B, Goraksha-Hicks, P, Diskin, SJ, Dellovin, DI, Simon, MC, Rathmell, JC, Lazar, MA, Maris, JM, Felsher, DW, 
Hogenesch, JB, Weljie AM, Dang CV. MYC disrupts the circadian clock and metabolism in cancer cells Cell Metab. 
In press. *Co-first authors. 
!! Hsieh, AL, Walton, ZE, Altman, BJ, Stine, ZE, Dang, CV. MYC and metabolism on the path to cancer. Semin Cell 
Dev Biol. Aug 2015 
!! Xiang, Y, Stine, ZE, Xia, J, Lu, Y, O’connor, RS, Altman, BJ, Hsieh, AL, Gouw, AM, Thomas, AG, Gao, P, Sun, L, 
Song, L, Yan, B, Slusher, BS, Zhuo, J, Ooi, LL, Lee, CGL, Mancuso, A, Mccallion, AS, Le, A, Milone, M, Rayport, 
S, Felsher, D, Dang CV.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous 
tumorigenesis. J Clin Invest. April 2015 
!! Stine, ZE, Walton, ZE, Altman, BJ, Hsieh, AL, Dang, CV. MYC, Metabolism and Cancer. Cancer Discov. In press. 
!! Hsieh, AL, Dang, CV. MYC, Metabolism and Cancer In Metabolism in Cancer. In press. 
!! Walton, ZE, Hsieh, AL, Dang, CV. Metabolism of hematologic neoplastic cells. In Williams Hematology 9th edition 
(Chapter 14). In press.  
!! Gouw, AM, Hsieh, AL, Stine, ZE, Dang, CV. (2015) MYC regulation of metabolism and cancer. In Tumor cell 
metabolism (pp. 101-122), S. Mazurek and M. Shoshan (Eds). Springer-Verlag Wien. 2015 
!! Stine, ZE, Altman, BJ, Hsieh, AL, Gouw, AM and Dang, CV. (2014) Deregulation of the cellular energetics of cancer 
cells. In Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (pp. 444-455), W. 
Coleman (Ed.). Elsevier. 2014  
 
PRESENTATIONS                                                                                         
Oral Presentations 
!! Hsieh, AL, Altman, BJ, Venkataraman, A, Gouw, AM, Stine, ZE, Li, B, Goraksha-Hicks, P, Diskin, SJ, Bellovin, DI, 
Hogenesch, JB, Simon, MC, Rathmell, JC, Lazar, MA, Maris, JM, Felsher, DW, Dang, CV. Oncogenic c- and N-Myc 
Disrupt Circadian Rhythm. Keystone Symposia: Molecular Clockworks and the Regulation of Cardio-Metabolic 
Function, Snowbird, Utah, April 2013 
Poster Presentations 
!! Hsieh, AL, Zheng X, Sehgal A, Dang CV. Drosophila Myc regulates circadian locomotor behavior in flies. Gordon 
Research Conference, Chronobiology, Girona, Spain, June, 2015 
!! Altman, BJ, Hsieh, AL, Stine, ZE, Gouw, AM, Venkataraman, A, Li, B, Goraksha-Hicks, P, Diskin, SJ, Bellovin, DI, 
Simon, MC, Rathmell, JC, Lazar, MA, Maris, JM, Felsher, DW, Hogenesch, JB, Dang, CV. MYC and MYCN 
disruption of the molecular clock in cancer cells. Annual Society for Neuro-Oncology (SNO) Scientific meeting, 
Miami, Florida, November, 2014 
!! Altman, BJ, Hsieh, AL, Gouw, AM, Stine, ZE, Venkataraman, A, Bellovin, DI, Diskin, SJ, Lu, W, Zhang, S, Felsher, 
DW, Maris, JM, Lazar, MA, Rabinowitz, JD, Hogenesch, JB, Dang, CV. Rev-erbα modulates Myc-driven cancer cell 
growth and altered metabolism. American Association of Cancer Research (AACR) annual meeting, San Diego, 
California, April, 2014 
!! Hsieh, AL, Altman, BJ, Venkataraman, A, Bellovin, DI, Felsher, DW, Hogenesch, JB, Dang, CV. Oncogenic Myc 
disrupts NAMPT circadian oscillation in mouse hepatocellular carcinoma cell line. American Association of Cancer 
Research (AACR) annual meeting, San Diego, California, April, 2014 
!! Hsieh, AL, Altman, BJ, Venkataraman, A, Gouw, AM, Stine, ZE, Li, B, Goraksha-Hicks, P, Diskin, SJ, Bellovin, DI, 
Hogenesch, JB, Simon, MC, Rathmell, JC, Lazar, MA, Maris, JM, Felsher, DW, Dang, CV. Oncogenic c-Myc 
Disrupts Circadian Rhythm. ASCI/AAP joint meeting, Chicago, Illinois, April, 2013 





!! Gouw, AM, Hsieh, AL, Zeller, K, Le, A, Higashi, R, Lane, A, Fan, TW, Wolfgang, M, Dang, CV.  Myc suppresses 
fatty acid oxidation and directly stimulates lipogenesis in human P493 B cells. AACR Metabolism and Cancer 
meeting, Baltimore, Maryland, October, 2011 
 
HONORS/AWARDS                                                                                                           
!! ASCI/AAP Joint Meeting Travel Award for excellent scientific abstract 2013 
!! Best Intern in Tzu Chi University awarded to top 3 students in the class with outstanding 
performance during clinical rotations voted by attending physicians, residents and nurses. 
2010 
!! GlaxoSmithKline Talent Scholarship awarded to one student from each medical school for 
outstanding academic performance. 
2009 
!! National Outstanding Youth of Taiwan awarded by the president of the Republic of China for 
extraordinary academic and extracurricular performance 
2009 
!! Best clinical history taking award at the Objective Structured Clinical Examination international 
competition held by Shanghai Jiao Tong University, China. Chosen by the faculty as one of 4 
medical students to represent school to participate this competition. 
2008 
!! Outstanding Award in the Summer Research Program for Medical Students awarded for 
significant research progress and excellent scientific presentation 
2007 
!! Dean’s List awarded to top 5 students in the class per semester 2003 – 2005 
 
PROFESSIONAL ASSOCIATIONS                                                                      
!! Amer ican Academy of Neurology 2014-Present 
!! Amer ican Association for  Cancer  Research 2011-Present 
!! Society for  Neuro-Oncology 2014-2015 
!! Amer ican Physician Scientists Association 2011-Present 
!! Amer ican Medical Association 2014-Present 
 
LEADERSHIP POSITIONS                                                                         
American Physician Scientist Association (APSA) Membership Committee, Vice-Chair 
!! Organized interactive sessions with prominent physician scientists to share experiences and career 
advice. Past speakers included Dr. Francis Collins, Dr. Alice Chen-Plotkin, Dr. Mukesh Jain and 
Dr. Ken Kaushansky. 
2014-Present 
JHMI Graduate Student Association, Treasurer 
!! Encouraged students to submit applications, reviewed applications, set up selection committee and 
selected awardee for GSA travel award four times a year. 
2011-2012 
TCU Student Association of School of Medicine, Executive secretary 
!! Coordinated one-week events including poster exhibition, introduction of historical medical 
devices and activities to practice suturing techniques using the pig skin 




PUBLIC HEALTH EXPERIENCE                                                                     
Let Love fly - Community medical mission project, Manila, Philippines 
!! Applied and received funding from Ministry of Education in Taiwan 
!! Initiated collaboration with local non-governmental organization Gawad Kalinga to help build 
houses for homeless families in the Philippines 
!! Organized summer camp to introduce hygiene concepts including hand washing and foot 
protection to children from low-income families 
!! Assisted in the free cataract surgery clinic through the Tzu Chi International Medical Association 
2008 
Tzu Chi Earthquake relief program, Yogyakarta, Indonesia 
!! Provided emotional support to victims, delivered food aid and assisted wound care through the Tzu 
Chi International Medical Association 
2007 




Elementary School Reading-Promotion Outreach Program 
!! Initiated project, organized educational outreach program for economically disadvantaged students 
and designed interactive activities to promote reading. 
2006-2007 
 
HOBBIES & INTERESTS                              
Ballroom dancing: 6th place in Bronze Foxtrot, Princeton Ballroom Competition, 2013; Tzu Chi Univer sity Chorus 
Group: Conductor, 2004
